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Abstract 
 
In this thesis, biological and imaging studies have been carried out on a supramolecular 
helicate (iron cylinder) and indirect methods to image this non-fluorescent compound 
have been developed. The iron cylinder has been investigated as a quencher of nuclear 
Hoechst fluorescence in a range of cancer cell lines. Flow cytometry and epifluorescence 
data has shown quenching occurring in a concentration-dependent manner at both the 
population and cellular level. These results provide evidence for the cylinder being able 
to interact in close proximity to the DNA within 20 minutes of administration. Using 
luciferase-expressing breast cancer cells, the iron cylinder has been shown to directly 
affect light emission in a concentration-dependent manner, an inhibition that has not 
previously been investigated providing further opportunities for imaging by monitoring 
the inhibition of luminescent enzymes. Furthermore, iron cylinder has been shown to 
quench GFP fluorescence using fluorimetry and confocal microscopy providing novel 
possibilities supporting the imaging of non-fluorescent compounds indirectly through the 
use of fluorescent stains. This thesis has also pioneered the first in vivo research relating 
to the iron cylinder in the model organism, zebrafish, and findings indicate a large 
therapeutic window over which the cylinder can bring about its effects.  
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Introduction 
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1.1 DNA (Deoxyribonucleic Acid) 
The self-assembled helical structure of DNA was proposed by James Watson and Francis 
Crick in 1953. DNA is composed of a string of nucleotides which in turn are made up of 
3 subunits: a ribose sugar (deoxyribose for DNA or ribose for RNA), a nitrogen base and 
a phosphate group.
1
 Two types of nitrogenous bases can be present in the DNA/RNA and 
these are purines and pyrimidines. Pyrimidines are single 6-membered rings and include 
uracil, cytosine and thymine while purines are composed of a fused 5 and 6-membered 
heterocyclic ring and include adenine and guanine. Thymine is present only in DNA, 
while uracil takes its place in RNA (Figure 1.1).
1
  
 
Figure 1.1. The composition of a nucleotide: a sugar, a phosphate group and a 
nitrogenous base. Taken from ref 2. 
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In the Watson-Crick B-DNA duplex, two sugar-phosphate backbones run in antiparallel 
directions with one going from 5’ to 3’ and the complementary strand running from 3’, to 
5’. The strands twist together to form the double helical structure of the DNA molecule 
which is stabilized by hydrogen bonding occurring between bases. Two hydrogen bonds 
are formed between adenine which pairs with thymine and three form between cytosine 
which pairs with guanine (Figure 1.2). Further hydrogen bonding is possible from the 
exposed outer edges of the bases and proteins and other molecules important in DNA 
expression and replication can easily access the DNA via these hydrogen bonds.
3
 The 
structure is further stabilized by ᴨ-stacking interactions with bases above and below in 
the helix, and interactions of the hydrophilic sugar-phosphate backbone of the polyanion 
with the solvent and counter cations such as Na
+
, K
+
, Mg
2+
.    
  
 
Figure 1.2. The DNA double helix. Taken from ref 2. 
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When the two strands of the DNA molecule twist together to form the helix, the exact 
dimensions and geometries can lead to different conformations. The most common form 
that occurs in living organisms is right-handed B-DNA in which the major groove of 
DNA is formed where the sugar-phosphate backbones are far apart on one side of the 
double helix and the minor groove forms where they are closer together.
2
 Two other 
conformations known as A-DNA and Z-DNA also exist (Figure 1.3). The A-DNA occurs 
rarely in living organisms and is a shorter, wider form of DNA. When the first X-ray 
crystal structure of DNA was identified in 1979, it was seen in the left-handed Z-DNA 
conformation which is a transient form of the molecule later found to be stabilized by 
negative supercoiling.
2,4
 Strong binding of specific proteins to the Z form of DNA have 
indicated it has a crucial role in protection against viruses.
2 
 
 
Figure 1.3. A-DNA, B-DNA and Z-DNA conformations of the double-stranded helix. 
Taken from ref 2. 
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Some unusual DNA structures such as G-quadruplexes are formed during biological 
processes including replication and transcription (Figure 1.4). These 4-stranded DNA 
structures are formed from hydrogen-bonded guanine bases in guanine-rich regions of 
DNA sequences. Repeated sequences of nucleotides known as telomeres cap the end of 
chromosomes protecting them from degradation. During replication of DNA, the strands 
of the double helix become shorter and upon telomere loss the cell undergoes death.
5
 
Maintenance of telomere length through overexpression of the telomerase enzyme leads 
to a continually replicating cell causing cancer. In the presence of cations, G-quadruplex 
structures may form in telomeric regions of DNA, thereby inhibiting the action of 
telomerase enzymes. Furthermore, the promoter region of the proto-oncogene, c-myc has 
been linked to many cancers. The presence of G-quadruplexes in these regions can 
prevent binding of proteins linked to cancer development.
6
   
 
 
Figure 1.4. Guanine base positions in a G-quadruplex with a centrally located cation. 
Hydrogen bonding is indicated by the dotted lines. Taken from ref 7.  
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1.2 DNA-Binding Agents 
The process of transcription is crucial for protein synthesis and in order to occur it 
requires numerous interactions between DNA and proteins. There has been much 
research focussed on identifying and developing small molecules that can inhibit this 
process and to understand the mechanism involved by which they interact with DNA. 
Covalent or non-covalent binding of small molecules to DNA helices can occur. A non-
covalent interaction with the DNA molecule is often reversible whereas production of an 
adduct leading to a permanent alteration at the DNA site occurs as a result of covalent 
binding. There are 4 main types of non-covalent ligand interactions with DNA. These 
include electrostatic interactions with the sugar-phosphate backbone, intercalation, major 
groove interactions and minor groove interactions.
8
   
 
Non-covalent intercalation is the process by which small molecules can insert between 
base pairs of DNA which lengthens the DNA and reduces the twist of the helix. This 
causes unwinding of the DNA which inhibits the enzyme topoisomerase that normally 
regulates DNA winding and unwinding. Replication and transcription are inhibited 
leading to cellular death.
9
 Intercalators need to be at least partially planar and the 
interaction is often mediated by some additional hydrogen bonds.
10
  
 
Due to poor specificity of most intercalators resulting in severe side effects, very few 
reach clinical drug status. However, new molecular structures are sometimes discovered 
which show a preference to specific sequences and these are very useful in the design of 
novel compounds.
10
 One such example is that of the antimalarial drug, Cryptolepine 
  
7 
 
(Figure 1.5). This indoloquinoline alkaloid intercalates into DNA at guanine-cytosine rich 
sequences and cytosine-cytosine sites.
11
 It is believed to interfere with the binding of the 
transcription factor, NF-KB to DNA and thereby inhibiting NF-KB mediated gene 
expression.
12
    
 
 
 
 
 
Figure 1.5. The structure of the antimalarial drug, Cryptolepine. 
 
DNA minor groove binders have received much attention over the past years as opposed 
to major groove binders largely due to the discovery of natural small molecules.
8
 
Examples include distamycin and netropsin (Figure 1.6) which form hydrophobic 
interactions and hydrogen bonds with AT-rich areas in the minor groove of DNA. The 
readily used bisbenzimidazole Hoechst dyes (Figure 1.7)  also bind to the minor grooves 
of DNA with specificity to AT regions causing the minor groove to become wider. In 
mammalian cells, Hoechst causes DNA strand breaks, induces protein- DNA crosslinking 
and arrest of the cell cycle in the G2 phase.
13
    
 
 
 
 
H
3
C 
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Figure 1.6. The structure of (A) Distamycin and (B) Netropsin.
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Figure 1.7. The structure of Hoechst dyes. Taken from ref 13.
  
 
The anti-tumor drug, azinomycin B (Figure 1.8) forms interstrand crosslinks with the 
DNA helix and transfers alkyl groups at guanine residues in duplex DNA. Bis-alkylation 
of N7 positions of guanine residues in the major groove are caused by 2 electrophilic 
sites on azinomycin B. Another anti-cancer drug, ditercalinium is a dimer which binds 
via the major groove through bis-intercalation between base pairs (Figure 1.9). This non-
alkylating compound is derived from the natural product, ellipticine. Upon interaction, 
the DNA duplex becomes bent in the direction of the major groove and X-ray 
crystallography has identified widening of the major and minor groove in addition to 
unwinding of the DNA helix.
8
      
 
 
Figure 1.8. Electrophilic sites of the major groove binder, Azinomycin B. Taken from ref 
8. 
  
10 
 
 
Figure 1.9. The structure of Ditercalinium.  
 
With regards to DNA binding and targeting, much research has focussed on compounds 
that interact directly with the nitrogenous bases and recognize specific sequences. Despite 
this, other regions of the DNA molecule can be targeted to achieve stronger binding with 
more specificity. Researchers used a novel DNA ligand called TriplatinNC (a trinuclear 
platinum complex) (Figure 1.10) which did not bind to DNA grooves or intercalate with 
DNA but instead bound to phosphate oxygen atoms and associated with the sugar-
phosphate backbone of DNA.
14
 Here, 3 square [planar tetra-amine platinum (II)] 
coordination units are separated by a spacer of 8 carbons and interact with the phosphate 
oxygen atoms of DNA. This mode of binding was referred to as a phosphate clamp 
(Figure 1.11). TriplatinNC extended along the minor groove and the DNA bent towards 
the major groove by electrostatic forces involved.
14 
  
11 
 
 
Figure 1.10.  The structure of TriplatinNC. 
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Figure 1.11. A phosphate clamp representing a phosphate oxygen atom accepting 2 
hydrogens from an amine group. Red: Oxygen. Blue: Nitrogen. Yellow: Phosphorous and 
White: Pt. Taken from ref 14. 
 
1.3 DNA Fluorescent Probes 
Techniques including X-ray crystallography and nuclear magnetic resonance 
spectroscopy have provided information about the physical, chemical and structural 
properties of DNA. However, it is not possible to image in real-time using these methods 
and resolution is limited. Fluorescence provides a different way to study the structural 
and functional properties of DNA and allows real time measurements to be obtained. 
Spectroscopy allows cellular processes to be monitored at the DNA level using a 
fluorescent probe which is incorporated into a specific site of the molecule. As DNA is 
not naturally fluorescent, the fluorescent signal does not have to compete with any 
biological signal.
15 
Many DNA fluorescent probes have been used in research to gain a 
better understanding of DNA binding and drug interactions.
15
 Classic nucleic acid stains 
can be grouped by their interactions with DNA and include minor groove binders 
(Hoechst dyes and DAPI), intercalators (ethidium bromide and propidium iodide) as well 
as other stains such as acridine orange and hydroxystilbamidine.
16
 
 
  
13 
 
Studies on complexes between the fluorescent DNA probe, DAPI (Figure 1.12) and DNA 
have shown a range of interactions with differing strengths and specificities. The exact 
sequence of DNA with which DAPI interacts has a strong influence on the mode of DNA 
binding. Minor groove binding, major groove binding and intercalation have all been 
identified when different sequences of DNA have been used. The presence of 4 
sequential AT/TA sequences are believed to be required for DAPI to bind in the minor 
groove of DNA. If the DNA sequence only consists of GC regions, DAPI is believed to 
intercalate between the base pairs.
17
 
 
A recent study used the process of solvation (association of solvent molecules with solute 
ions) as a novel way of investigating binding of DAPI to 2 different DNA sequences. The 
sequence of oligomer 1 contained an AT rich region and oligomer 2 was made of only 
GC base pairs. Solvation relaxation times for DAPI bound to oligomer 1 were similar to 
the well-researched minor groove binder Hoechst 33258. Solvation did not occur with 
oligomer 2 within the time frame examined. This together with an extended lifetime of 
DAPI in complex and fluorescence quenching due to electron transfer from GC bases to 
DAPI correlates with the dye intercalating with DNA. This study provided evidence for 
two independent binding modes of DAPI with DNA by looking at the dynamics of the 
sequence-dependent complexes formed.
17
   
 
 
 
Figure 1.12. The structure of DAPI. 
 
+ 
+ 
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DNA detection methods often involve a fluorescent signal produced by the hybridization 
of a nucleic acid probe to a complementary sequence of single stranded DNA. TaqMan 
probes and molecular beacons are examples of these. Double stranded DNA sequences 
can also be detected using fluorescence methods and results can be more specific than 
those obtained from methods where all the DNA is denatured.
18
 Recently duplex DNA 
was opened at a target site using a pair of peptide nucleic acid openers and thereby 
exposing one of the strands. As this DNA region was now single stranded, the sequence 
could be directly detected using a molecular beacon probe which hybridized to it leading 
to the production of a ‘PD-loop’ structure (Figure 1.13).18    
 
High specificity is achieved as the PD loop structure requires independent recognition by 
the molecular beacon probe and two peptide nucleic acid openers. Once opened, a 
circular oligonucleotide probe was assembled onto the single stranded sequence which 
provided a template for rolling circle amplification (Figure 1.13). This resulted in the 
production of a long single stranded continuous DNA molecule containing multiple 
copies of the sequence complementary to the circular DNA. This approach was 
successfully used to identify marker sequences in plasmid DNA in the absence of false 
positives. Peptide nucleic acid openers can only act on homopurine sites and therefore 
only specific target sites can be detected using this method.
18 
 
  
15 
 
 
Figure 1.13. (A) The structure of a PD loop formed at opening site of double-stranded 
DNA by a pair of peptide nucleic acid openers followed by hybridization with a 
molecular beacon probe. (B) Circular probe assembling at the opened target site. Taken 
from ref 18. 
 
Fluorescence and confocal laser scanning microscopy are routinely used to directly 
visualize nucleic acid staining and confocal offers several advantages when compared to 
conventional fluorescence microscopy including optical sectioning where focussed 
images from selected depths can be captured and 3D reconstructions can be acquired.
19
   
Two dyes readily used in immunofluorescence microscopy are rhodamine and fluorescein 
which emit red or green fluorescence respectively. As mentioned previously a range of 
dyes that recognise nucleic acids have been developed. One study compared the 
suitability of 5 such stains (TOTO-3, TO-PRO-3, YO-PRO-1, SYBR Green I and 
propidium iodide) for histochemical staining and visualization by confocal or 
fluorescence microscopy.
20
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As propidium iodide intercalates between bases, it stains RNA in addition to DNA and 
therefore cytoplasmic staining occurred in samples that received no RNAse treatment. 
Furthermore, tissues such as pancreatic samples with high levels of cytoplasmic RNA 
required further RNA digestion when propidium iodide was chosen as a nucleic acid 
stain. The SYBR Green I dye which binds preferentially to double stranded DNA 
strongly stained nuclei of cells examined and appeared as a bright green fluorescence. 
This was used successfully together with the red immunofluorescent stain, rhodamine and 
a clear contrast was achieved. SYBR Green I stained cells revealed very little staining of 
cytoplasmic RNA and therefore samples did not require RNAse treatment. Image capture 
with this dye had to be done quickly as the fluorescent signal was rapidly lost and this 
was noted as a disadvantage when using this dye for microscopy.
20
 The membrane-
impermeable carbocyanine dye, YO-PRO-1 also showed as a green fluorescence when 
bound to DNA. The signal faded less quickly than that seen for SYBR Green I stained 
cells but RNAse treatment was required as YO-PRO-1 had a higher affinity for RNA than 
SYBR Green I.
20
  
 
Imaging the red and green nucleic acid stains (propidium iodide, SYBR Green I or YO-
PRO-1) using fluorescence microscopy allowed only one fluorescent immunostain to be 
used in combination. Triple staining such as that achieved with two immunostains and a 
DNA stain was carried out using the two far-red fluorescent DNA dyes, TOTO-3 and 
TO-PRO-3. TOTO-3 staining of DNA was weaker than that observed for any other 
nucleic acid stain. Furthermore, RNA in the nucleus and cytoplasm were strongly stained 
when using this dye requiring RNA digestion of samples. Despite this, the fluorescent 
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signal produced by TOTO-3 was more stable than that produced by the other stains. 
Finally, TO-PRO-3 revealed strong, highly-specific DNA staining but the signal 
degraded rapidly and therefore images needed to be captured quickly.
20 
 
Research has also been carried out on fluorescent dyes that have the ability to distinguish 
between specific structural conformations of DNA. Double stranded DNA has been a 
popular target for many fluorescent probes with the majority of molecules intercalating 
between base pairs and therefore spanning the distance of a base pair. Quadruplexes are 4 
stranded structures of DNA containing 4 grooves. Single stranded DNA can be 
distinguished from quadruplex structures using circular dichroism by measuring the 
difference between absorption of left and right-handed circularly polarized light.
21
 Raman 
spectroscopy which relies on the scattering of light has also been used to look at 
quadruplex DNA specifically.
21 
 
A study recently investigated molecules spanning 4 bases as specific binders of 
quadruplex DNA.
21
 Previously, it had been shown that nucleic acid aptamers containing 
sequences that could form quadruplexes, bound to porphyrins with high specificity.
22
 
Therefore, porphyrins binding specifically to quadruplexes were investigated in a mixture 
containing other DNA structures including single and double stranded DNA. The 2 
specific porphyrins investigated were T4 and NMM (Figure 1.14).
21
 It was previously 
shown that some porphyrins could bind to double stranded structures but do so in 
between bases on the same DNA strand as opposed to intercalating between base pairs of 
both strands of the helix.
23 
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Figure 1.14. The structure of porphyrins: (A) NMM and (B) T4. Taken from ref 21.  
 
2 kinds of quadruplex DNA (a 12mer basket form and a 15mer chair form) were used and 
the binding of the porphyrins to these structures was compared to that with duplex DNA 
(Figure 1.15). A substantial increase in fluorescence was observed for NMM in the 
presence of both types of quadruplexes and no fluorescence increase was seen with calf 
thymus duplex DNA. A slight increase in T4 fluorescence occurred in the presence of 
duplex DNA and no increase was observed in the presence of the 12mer DNA. However, 
a significant enhancement in T4 fluorescence was seen with the 15mer DNA. These 
results showed that all quadruplex structures caused a substantial increase in the 
fluorescence of NMM but duplex structures were not able to do this. Duplex DNA was 
able to increase fluorescence of T4 to a greater extent than basket form quadruplexes and 
chair type quadruplexes significantly enhanced T4 fluorescence. In their free states, 
neither T4, nor NMM showed high fluorescence.
21 
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Figure 1.15. Quadruplex types: (A) Basket type DNA formed by 12mer 
d(GGGGTTTTGGGG). (B) Chair type formed by 15mer d(GGTTGGTGTGGTTGG). 
Taken from ref 21. 
 
Results from this study showed that fluorescent porphyrin probes could be used to screen 
for quadruplex DNA in a mixture containing other structures. Despite not having absolute 
specificity, the dyes did show high specificity. By using both T4 and NMM, the presence 
and estimated percentage of quadruplex DNA in a mixture could be determined. These 
dyes can further be used to monitor how quickly quadruplexes may form as a result of 
specific influences. Furthermore, studying the displacement of dye from DNA can 
provide further insight into the dynamics of protein-quadruplex complexes. Other 
interesting observations were made during the course of this study including a drastic 
increase seen in the fluorescence of T4 in the presence of potassium.
21
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1.4 DNA as a Target for Anticancer Compounds 
Nucleic acids are crucial to the processes of DNA replication and protein synthesis 
(transcription and translation) which occur in both healthy and cancerous cells. DNA has 
long been a target of anti-cancer drugs with some directly interacting with it and others 
inhibiting the enzymes responsible for its structure and processing. Topoisomerase 
inhibitors including doxorubicin and etoposides, alkylating agents such as nitrogen 
mustard, antimetabolites including the folic acid antagonist, methotrexate and covalent 
modifiers of DNA such as platinum compounds all cause non-specific damage and are 
used extensively as effective anticancer drugs.
 
Furthermore, DNA is also the major target 
for γ-irradiation.24 
  
DNA is believed to be the central unit responsible for driving tumour development and 
growth. There are a number of reasons as to why it is chosen as a primary target when 
developing novel chemotherapeutics. It is the material which is damaged in cancer cells 
through the process of genetic mutations as well as variations occurring in the length of 
its cycle when compared with healthy cells. In addition, due to increased DNA 
replication and errors in cell cycle control/ DNA repair processes, cancer cells are more 
likely to obtain extra DNA damage than normal cells making DNA an ideal target for 
cancer treatment.
24
   
 
Despite being an ideal target for cancer drugs, there are several concerns when targeting 
DNA. In addition to severe side effects of treatment and development of secondary 
tumours, treatment does not provide a cure for the disease. The majority of treatment 
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available causes intense damage to DNA and so reducing this would decrease side effects 
as well as increasing the chances of achieving a curable situation. If drugs available were 
more specific in their interaction with DNA, the large number of mutations produced 
would be minimized. Therefore, much novel research is trying to develop strategies to 
alter the mechanism by which DNA is targeted by anticancer treatment.
24 
 
 
Quinacrine (Figure 1.16) was first discovered in the 1920s as an antimalarial drug. Later, 
its anti-inflammatory activity was noted and used in the treatment of autoimmune 
conditions including systemic lupus erythematosus. Recently quinacrine was tested for its 
anticancer activity by P53 activation. P53 is a tumour suppressor gene which stops the 
cell cycle to allow repair of damaged DNA or induces apoptotic pathways if the damage 
is beyond repair. Quinacrine was found to induce P53 activation and also activated P53-
dependent genes downstream. Furthermore, it showed greater toxicity to tumour cells 
than healthy cells.
24
 
 
Figure 1.16. The structure of Quinacrine.  
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Previously, quinacrine had been classed as a DNA-damaging agent known to intercalate 
with DNA. However, this particular study found no evidence of quinacrine-induced DNA 
damage in mammalian cells. A number of assays were used to confirm this including the 
bacterial mutagenicity, ames test and the comet assay which showed no difference in 
number of strand breaks as a result of treatment when compared to the control. In 
addition, no H2AX histone phosphorylation occurred and no activation of the 
serine/threonine kinase, ATM occurred which would normally happen in response to 
DNA strand breaks. Furthermore, quinacrine offered protection from toxicity caused by 
the DNA-damaging agents, bleomycin and doxorubicin in eukaryotic cells. In vivo 
studies also supported these findings where quinacrine did not promote tumour growth in 
P53 deficient mice which normally show high levels of radiation induced tumour 
development. These findings highlight the fact that the cytotoxicity of a compound that 
binds to DNA is not always a result of genotoxic effects or DNA damage. The 
mechanism by which quinacrine has these anticancer activities was further investigated.
24
  
 
Quinacrine has been found to interact with both nucleic acids and phospholipid bilayers. 
Methods including calorimetry, structural studies and FRET (fluorescence resonance 
energy transfer) have been used to study its intercalation with DNA. Quinacrine increases 
the length of DNA and keeps the helical structure stable thereby preventing temperature-
induced strand separation. During DNA replication, frame shift mutations can occur in 
the pre-disposed intercalator-DNA complex. However, as quinacrine inhibits the DNA 
polymerase I enzyme and therefore replication, this mutagenicity does not occur in 
quinacrine-treated mammalian cells.
24
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In addition to the planar tricyclic structure which intercalates with DNA, quinacrine also 
has a tail structure which is believed to protrude into the minor groove further 
strengthening its binding to DNA. High specificity for AT-rich regions is seen when 
quinacrine interacts with DNA which is similar to the HMG (high mobility group) group 
of proteins that bend DNA. 2 enantiomers of quinacrine leads to 2 alternative positions 
for the ‘tail’ part of the molecule in the minor groove. The R-enantiomer which is 
directed along the minor groove fits better and shows stronger activation of P53 and 
inhibition of NF-KB (transcriptional activator) than the S-enantiomer which is positioned 
in the opposing direction to the groove. Furthermore, a higher affinity for DNA binding 
has been found with the R-enantiomer. Using the evidence obtained, researchers  
proposed a mechanism by which quinacrine effectively kills tumour cells.
24
 
    
This mechanism involves initial intercalation of the drug with its ‘tail’ binding to AT-rich 
sequences in the minor groove. The binding results in reduced movement of the DNA 
molecule and interferes with HMG protein function. This leads to inhibition of 
transcription factors that require certain DNA conformations to bind and specific contact 
with the HMG proteins. These include HSF1 and NF-KB which are important factors in 
tumour cell growth and development. The FACT (facilitates chromatin transcription) 
protein complex also recognizes the quinacrine-DNA complex and causes P53 activation. 
Specificity of quinacrine for cancer cells may be due to the fact that many of the 
transcriptional pathways involved are not required by healthy tissues. Quinacrine offers a 
very promising mechanism for effective anticancer treatment.
24
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Another potent anticancer drug, ellipticine (Figure 1.17) was recently investigated in 
terms of its binding and interaction with DNA.
25
 Earlier studies using X-ray 
crystallography showed ellipticine complexed with a self-complementary 
ribodinucleoside monophosphate.
25
 The interaction appeared similar to that of 
cryptolepine showing intercalation parallel to the hydrogen bonds of base pairs with the 
aromatic rings stacking into the bases. However, in this study, oligonucleotides of very 
short lengths were used and therefore, the structure’s true representation of the mode by 
which ellipticine binds DNA was debated.
25
  
 
This study concluded that the intercalation caused DNA unwinding and lengthening to 
occur. With ellipticine bound in complex, the DNA conformation is in the B-form. 
Despite this, to accommodate the intercalation of ellipticine, the DNA helix twists 
slightly at the two sites by 21
o
. The sugar phosphate backbone of DNA becomes distorted 
to open the bases at both sites by around 7 Å. This study suggested that derivatives of 
ellipticine with similar structures would bind in the same way to form complexes with 
DNA. However, further structural research into such interactions would be necessary to 
confirm this.
25
     
 
 
 
 
 
Figure 1.17. The structure of Ellipticine. 
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1.5 Cisplatin 
The anticancer properties of cisplatin were identified by serendipity in the late 1960s 
when the microbiologist, Barnett Rosenberg was investigating the effects of electric 
fields on bacterial cell division.
26
 Cisplatin was produced electrochemically by cell 
culture media components and the platinum electrodes where it was found to inhibit 
E.coli growth.
27
 In 1969, the discovery was made that cisplatin had the ability to 
completely stop growth of solid sarcomas and this was published in Nature.
26
 Following 
clinical studies, in 1978 the FDA granted approval for this drug to be used in clinic and 
currently it is the most commonly used anticancer agent in the world.
28
 The structure of 
cisplatin contains a platinum ion surrounded by the four ligands, two chlorides and two 
amines.
29
 This drug provides a good example of the drastic changes in biological activity 
that can occur when minor alterations are made in molecular structure. With the chlorides 
and the amines arranged consecutively (as shown in Figure 1.18), cisplatin functions as 
an anticancer agent. However, if the chlorides are arranged diagonally, separated by the 
amines, the compound has no biological activity.
29 
 
 
Figure 1.18. The structure of Cisplatin.  
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Cisplatin is believed to exert its anticancer effects and induce programmed cell death 
(apoptosis) through its interactions with DNA.
29,30
 When administered, cisplatin enters 
the bloodstream and encounters a high plasma chloride concentration. This prevents the 
process of aquation whereby the chloride ligands become replaced by water molecules. 
Despite this, proteins such as glutathione and albumin, especially those containing thiol 
groups target cisplatin, binding to it, causing chloride displacement and inhibiting its 
action.
30 
Cisplatin diffuses across the plasma membrane of cancer cells where the 
chloride concentration is low. Therefore, a chloride ligand becomes replaced by water 
and the resulting positively charged molecule is not able to exit the cell.
29
  
 
The interaction between cisplatin and DNA has been extensively studied. The N7 atoms 
of the purines of DNA base pairs coordinate to cisplatin as they do not form hydrogen 
bonds with any other bases (Figure 1.19). A number of different adducts may be formed 
with 1,2-intrastrands being the most common. These adducts form when cisplatin’s two 
chlorine ligands become replaced by nitrogen atoms of purines on adjacent bases from 
the same DNA strand. Two guanines are the most commonly involved in the formation of 
these adducts. Alternatively, adducts involving one guanine and one adenine are formed 
(Figure 1.20).
31
  Base destacking is associated with the GG or GA binding and leads to 
significant distortion of the DNA and this distortion is recognized by DNA- binding 
proteins. Cell cycle arrest and DNA repair mechanisms are triggered by the damage 
caused to the DNA and if the repair is not successful, apoptosis is triggered leading to 
cell removal.
32
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Figure 1.19. N7 position of Guanine.  
 
 
Figure 1.20. Crosslinking of cisplatin to form adducts.
 
Taken from ref 31. 
 
Cisplatin is successfully used to treat many solid tumours including, bladder, testicular, 
lung and head and neck cancers.
33, 34
 It has been found to be particularly active against 
testicular cancer and a cure rate of almost 100 % is reached if tumours are detected 
early.
35 
For non-small-cell lung carcinoma and melanoma, cisplatin is one of the most 
7  
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effective drugs used. Furthermore, when used in combination with other drugs, it is very 
active against ovarian cancer.
26
 Despite the therapeutic success of this platinum 
compound, many patients in clinic have shown intrinsic resistance to platinum-based 
therapies.
35
 In addition, a significant proportion of cisplatin- sensitive tumours gradually 
develop a resistance to the drug which is especially common in ovarian cancers.
36 
Despite 
the initial 70 % curable success rate when using cisplatin to treat ovarian cancer, this is 
reduced to 15–20% within five years as the tumour becomes resistant.37 
 
Cisplatin-induced interstrand crosslinks (ICLs) block transcription and replication in cells 
by preventing the DNA strands from separating. Fanconi anaemia has provided a greater 
understanding into the processes by which these lesions are repaired as cells taken from 
patients with this genetic condition show high sensitivity to interstrand crosslinks.
38
 
Activation of the Fanconi anaemia pathway is crucial in the repair process and involves 
identification of a stalled replication fork, removal of the lesion, homologous 
recombination and nucleotide excision repair.
39
 
 
Cisplatin resistance may occur through a variety of cellular events, including TLS 
(translational DNA synthesis). 4 TLS polymerases exist in humans (Polκ, Polɭ, Polη and 
Rev1) each with its own bypass for DNA damage and specific profile.
28
 Polη and Pol ζ (a 
member of the B-family of polymerases) are specialized polymerases which are able to 
replicate through the 1,2 intrastrand crosslink formed by cisplatin-DNA adducts.
40
 The 
process by which these two cause cisplatin resistance involves Polη inserting a cytosine 
base opposite the lesion site and Pol ζ then extending the structure fully bypassing the 
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lesion.
40
 Human Polη is potentially a very useful target for cancer treatment as it can 
replicate from a cisplatin-DNA adduct. Researchers are working to find specific 
inhibitors for this polymerase and as the cleft at its active site is more open than that of 
the other polymerases, it may be possible to identify small molecule inhibitors of Polη.28  
 
In addition to drug resistance, cisplatin’s use is strictly limited due to its severe side 
effects. These include nephrotoxicity, peripheral neurotoxicity, cardiotoxicity and 
myelosupression.
41 
Cisplatin-associated nephrotoxicity is believed to be caused by renal 
excretion of the drug. The terminal proximal tubule and distal nephron of the kidney 
accumulate a high concentration of cisplatin which induces necrotic or apoptotic cell 
death. Short exposures to the drug tend to cause necrosis with prolonged exposures 
leading to apoptosis.
27
 Ototoxicity is especially common in pediatric patients receiving 
cisplatin which causes damage to the cochlea’s outer hair cell reducing their function. 
The resulting production of reactive oxygen species and apoptosis activation in the inner 
ear is believed to be caused by induction of NOX3, a NADPH oxidase which resides in 
the cochlea. Increased production of the superoxide radical occurred when nox3 –
transfected kidney cells were treated with cisplatin. This is believed to cause ototoxicity 
when converted into hydrogen peroxide and the hydroxyl radical by enzymes present in 
the cells.
27
 When administered to patients, this drug has also been shown to cause a 
decrease in plasma antioxidant concentrations which can decrease the effectiveness of 
defence mechanisms against genotoxicity.
42
 As cisplatin is not specific in its action, 
genetic damage can result in unaffected tissues leading to accumulation of mutations and 
secondary tumors several years after cessation of treatment.
43 
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As with other drugs, cisplatin also has a family of related second and third generation 
compounds. Carboplatin which has been successfully used to treat ovarian cancer, is less 
toxic than cisplatin but still has high efficacy. Oxaliplatin is used for colorectal cancer in 
combination with other drugs and is effective for certain tumours that have developed 
resistance to cisplatin treatment (Figure 1.21).
26
 The drawbacks associated with cisplatin 
have prompted research into modifying the strategy used to target DNA to develop novel 
metal drugs focussing on alternative metals and new modes of interaction.
44 
As 
mentioned previously, developing drugs which bind to DNA but do not damage it, will 
prevent undesirable side effects such as those associated with cisplatin treatment.
24 
 
A 
 
 
 
B 
 
 
Figure 1.21. The structures of Carboplatin (A) and Oxaliplatin (B). 
  
31 
 
1.6 Supramolecular Chemistry 
Supramolecular chemistry is concerned with chemical systems consisting of assembled 
molecular subunits and explores larger structures containing weak and reversible 
noncovalent interactions between molecules.
45
 Examples of such interactions include: 
hydrogen bonds, hydrophobic forces, van der Waals forces and metal coordination.
46
 
Supramolecular chemistry is important in the understanding of molecular recognition and 
self-assembly, host-guest chemistry and mechanically-interlocked molecular 
architectures.
47
 As many biological interactions including those between the two strands 
of the DNA helix depend on these processes, research into noncovalent interactions is 
necessary to understand their structure and function.
46
  
 
The field of supramolecular chemistry has created many chemically appealing self-
assembled structures containing metals as the driving elements.
48
 The self-assembly 
process under thermodynamic control is attractive when compared to traditional multi-
step covalent organic synthesis and produces larger, ordered structures.
49 
Much work has 
focussed on the recognition of DNA by cylindrical metallo-supramolecular agents (see 
section 1.8).
49 
and has led to the creation of large synthetic structures which closely 
resemble the size and shape of protein DNA recognition motifs. Therefore, these agents 
are predicted to have novel DNA-binding properties and to display novel types of 
biological activity.
49,50
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1.7 Metal-based Drugs 
Many transition metals have been used in the design of anticancer drugs due to various 
properties they exhibit including a range of redox and spectroscopic properties as well as 
changeable coordination geometries. In recent years, photodynamic therapy using metal-
based photosensitizers able to photocleave DNA under conditions of visible light has led 
to the development of a number of platinum, dirhodium and ruthenium complexes. 
Recently, novel cobalt (II) complexes with terpyridine ligands made with phenyl, pyrenyl 
and anthracenyl moieties were synthesized and tested for their photochemotherapeutic 
properties (Figure 1.22).
51
  
 
 
 
 
 
 
 
 
Figure 1.22. The structures of cobalt (II) complexes. 
 
The complexes with pyrenyl and anthracenyl moieties bound strongly to calf thymus 
DNA and cleaved plasmid DNA when induced by visible light. Hydroxyl radicals were 
produced through a photo-redox pathway and in HeLa (cervical cancer) cells, a 
photodynamic therapeutic effect was seen. The photoactive pyrenyl and anthracenyl 
2+ 
    R = 
Phenyl 9-anthracenyl 1-pyrenyl 
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moieties aided cellular imaging and live-cell microscopy identified the complexes 
crossing the plasma membrane and accumulating in the cytoplasm. The amount taken 
into cells was less for the complex with the phenyl moiety. Toxicity studies for the light-
exposed pyrenyl cobalt (II) complex revealed a similar IC50 value to that of the popular 
cancer drug, cisplatin.
51 
 
Copper (II) complexes conjugated to ferrocene have also been synthesized and 
investigated in relation to their photocytotoxic activity under visible light conditions. 
Complexes lacking the ferrocene moiety showed reduced photocleavage of DNA and 
cytotoxicity against HeLa and MCF-7 (breast adenocarcinoma) cells when compared 
with ferrocene-appended complexes. A complex containing a napthyl fluorophore was 
successfully used for fluorescence microscopy to show uptake and nuclear localization of 
complexes in HeLa cells.
52
 
 
As many cellular enzymes and transcription factors have binding sites for zinc, the Zn 
(II) ion can potentially have an effect on many areas of cell signaling. In addition, 
previous studies have shown that zinc reduces the levels of metal-induced 
hepatotoxicity.
53
 Recently, macrobicyclic dinuclear zinc (II) complexes were investigated 
for their interaction with DNA and anticancer activity against HeLa and BeWo (placental 
cancer) cells.
54
 DNA-binding studies including circular dichroism, fluorescence and 
absorption spectral studies showed the zinc complexes interacted with calf thymus DNA 
through intercalation. The mechanism by which plasmid DNA was cleaved was studied 
in the presence of a hydroxyl radical scavenger (DMSO), a superoxide quencher (SOD) 
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and a singlet oxygen quencher (L-histidine). As the cleavage activity of complexes was 
not affected, an oxygen- independent hydrolytic mechanism was identified.
54
  
 
The strongest activity against cancer cells was displayed by complexes with 
macrobicyclic ligands containing phenanthroline (Figure 1.23). Results revealed that a 
complex’s ability to bind and cleave DNA required a synergistic interaction of metal ion 
and ligand which is important when designing anticancer drugs. Therefore, stacking of 
phenanthroline-coordinated complexes resulted in strong DNA binding, cleavage, 
efficient transfer across the plasma membrane and high toxicity against cancer cells. 
Furthermore, activation of caspase 3/caspase 9 and increased membrane permeability 
occurred with these compounds which are phenotypically associated with apoptotic 
induction.
54
 Further studies on uptake would be required to understand the precise 
mechanism by which these complexes cause cancer cell death.   
 
 
Figure 1.23. The structure of [Zn2L(phen)2(H2O)2](ClO4)4
 
(macrobicyclic dizinc (II) 
complex) Oxygen: red, Nitrogen: blue, Carbon: grey, Zinc: green. Taken from ref 54. 
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Another novel soluble Zinc (II) complex has recently been synthesized and its interaction 
with DNA has been studied. This complex was derived from the sulfa drug, sulfasalazine 
and the dipeptide, glycine-glycine.
55
 As they contain a range of donor centers including 
N-terminal oxygen atoms and carbonyl oxygens, peptides are good binders of metal ions. 
These properties of peptides have been exploited and combined with metals to be used as 
therapeutics. The anticancer drug, bleomycin is an example of a metallopeptide that 
shows strong DNA specificity.
55
 The structure of the complex was designed with several 
pharmacologically active properties including a metal-binding domain, the 
sulfasalazine’s planar rings which could partially intercalate into DNA and good 
solubility allowing efficient plasma membrane uptake.
55
 Binding studies for the zinc (II) 
complex in vitro revealed electrostatic interactions with DNA and preference for binding 
to AT-rich regions in the minor groove (Figure 1.24). A hydrolytic mechanism by which 
plasmid DNA was cleaved was suggested. The complex was able to recognize a specific 
sequence of DNA and therefore control gene expression via inhibition of overactive 
transcriptions factors.
55
 Designing new anticancer agents with well-defined properties 
could help move past resistance that has been displayed by many tumours against 
platinum drugs.         
 
Figure 1.24. Partial intercalation of zinc (II) complex with adjacent AT base pairs in 
DNA minor groove.
 
Taken from ref 55. 
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Ruthenium has received much attention as a metal of choice in the development of 
anticancer agents. This is due to its many advantageous properties including high cellular 
toxicity against cancer cells, low toxicity against healthy cells and many oxidation states. 
Currently, the two octahedral ruthenium complexes, KP1019 and NAMI-A have been 
successful in phase 1 of clinical trials (Figure 1.25).
56
 The anticancer activity of these 
complexes has been studied with various methods being proposed including DNA 
binding, metastatic growth inhibition, ROS production and activation of apoptotic 
signaling pathways.
57,58
 Biologically active imidazole derivatives are found in many 
naturally occurring products and have been used in ligand synthesis of metal complexes 
including that of NAMI-A.
56 
 
A       B 
 
 
 
 
 
 
 
 
Figure 1.25.  The structure of ruthenium complexes: (A) NAMI-A (B) KP1019.  
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In a recent study, 3 fluorescent ruthenium complexes (RuIP1, RuIP2, RuIP3) were 
synthesized with ligands made of imidazole derivatives and studied for their anticancer 
properties to try understand their mechanism of action at the molecular level (Figure 
1.26).
57
 Results showed all the complexes had strong anti-proliferative activity against 
HepG2 (hepatocellular carcinoma), A375 (melanoma) and SW480 (colorectal 
adenocarcinoma) cells. In addition, the complexes were not as toxic as cisplatin to 
healthy HK-2 (kidney) and HS68 (fibroblast) cells of humans. Cell cycle analysis 
confirmed apoptotic cell death as the method of cancer cell killing for the RuIP1 
complex. This was further confirmed by the Tunel assay which identified nuclear 
condensation and DNA fragmentation. Furthermore, the study found this complex was 
able to induce internal mitochondrial-associated and external receptor-associated 
apoptotic pathways in tumour cells making it a promising candidate for further 
investigation as a chemotherapeutic.
57
 
 
 
 
 
 
 
Figure 1.26.  The structure of 3 Ruthenium complexes: [Ru(L)2IP]
2+ 
(IP: imidazole[4,5-
f][1,10]phenanthroline) L: 2,2-biimidazole (biim); 2,2-bipyridine (bpy); 1,10-
phenanthroline (phen). 
 
biim 
RuIP1 
bpy 
RuIP2 
phen 
RuIP3 
= 
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A different approach to understanding how cells respond to metal-based anticancer drugs 
has been the synthesis of fluorescent versions of these drugs. Fluorescein-labelled 
derivatives of cisplatin have been synthesized and visualized inside cancer cells using 
fluorescence microscopy allowing researchers to overcome some of the obstacles 
associated with imaging localization of drugs in cells.
59
 Following on from this success, 
in a recent study, platinum (II) was co-ordinated to a fluorescent ligand (N,N-bis 
(anthracen-9-ylmethyl)propane-1,3-diamine) (bapda) and the complex’s anticancer 
activity was investigated in relation to cisplatin (Figure 1.27).
60
  
 
 
Figure 1.27.  The structure of cis-[Pt(bapda)Cl2].
 
Taken from ref 60. 
 
The complex showed strong antiproliferative activity in A2780 (ovarian carcinoma) with 
resistance seen in A2780R (cisplatin-resistance) cells, similar to that seen with cisplatin. 
Glutathione molecules are believed to play an important part in the resistance mechanism 
with cisplatin. However, with cis-[Pt(bapda)Cl2] no significant difference was observed 
in resistance to glutathione-depleted A2780R cells.
60
 Cisplatin is believed to interact with 
glutathione via chloride displacement (see section 1.5) but bapda is co-ordinated to Pt (II) 
through a chelating mechanism, making cis-[Pt(bapda)Cl2] stable against inhibition by 
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glutathione. Fluorescence quenching experiments where plasmid DNA and calf thymus 
DNA were added to solutions of cis-[Pt(bapda)Cl2] were carried out to investigate the 
complex’s ability to intercalate. Results revealed a drop in fluorescence when calf thymus 
DNA was used suggesting that anthracene rings were intercalating between base pairs.
60
 
  
Cisplatin’s success in clinic started the interest in metal-based chemotherapeutics with 
DNA as the target of choice. To date, many classes of metal have shown anticancer 
activity in vitro. These include gold (I,III), palladium (II), platinum (II,IV), ruthenium 
(II,III), rhenium (I), bismuth (III), copper (II), tin (IV) and gallium (III) derivatives.
61
 
Further improvements on drug design depends on specific targets, control of delivery and 
ideally a fluorescent version of each drug with the aim to improve cancer cell toxicity 
with minimal toxicity and better imaging in cells, tissues and organs.
61
      
 
1.8 Metallo-supramolecular Cylinders  
Cylindrical metallo-supramolecular agents able to recognize DNA have been designed 
and have the potential to be used as anticancer drugs.
48,62
 Supramolecular chemistry has 
allowed these structures to be created that are analogous in size to the DNA recognition 
portion of protein zinc fingers (such as an α-helix) with the hope that alternative 
mechanisms of DNA binding to cisplatin will bring alternative activity in tumour 
cells.
63,64
 Unlike the classic DNA-drug interactions mentioned above, they have been 
designed to be the right size (1 nm x 2 nm) and shape to fit perfectly into the major 
groove of DNA (spanning five base pairs) but too bulky to fit in the minor groove (Figure 
1.28).
65,66
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Figure 1.28. NMR structure of a cylinder in the major groove of DNA.
 
Taken from ref 49. 
 
The synthetic cylinders are made of two metal ions surrounded by three ligand strands 
and carry a tetra-cationic charge giving the formula [M2L3]
4+ 
with various metal ions used 
in their design (Figure 1.29).
49
 The dimetallic nature of these compounds means they 
carry a high positive charge which has been predicted to strengthen their binding to the 
negatively charged DNA molecule. The binding properties of these cylinders have been 
further investigated using the commonly used technique, circular dichroism (CD). This 
technique is defined as the difference in absorption between right and left-handed 
circularly polarized light.
67 
The CD is specifically affected by the chirality or asymmetry 
of an environment. Therefore, when a CD signal in the optical transitions of cylinder is 
observed for a racemic mixture of iron cylinder in the presence of DNA, it indicates that 
cylinder is binding to DNA. The CD spectra produced have shown the cylinder to be 
interacting with DNA in a single mode of binding which is consistent with binding in the 
major groove.
49
 Strong binding of cylinder to DNA has been indicated through the use of 
spectroscopic studies with a binding constant in excess of 10
7 
M
-1
.
66
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Figure 1.29. A tetracationic triple-stranded supramolecular cylinder.  
 
Linear dichroism (LD) has also been used to analyse the orientation of the cylinder on the 
DNA.
49
 LD is defined as the unequal absorption of light polarized parallel and 
perpendicular to an orientation axis.
68 
A molecule bound to DNA in a particular 
orientation will also be oriented by the viscous drag and therefore a LD signal is 
produced. In comparison, a molecule that is unattached or randomly associated with 
DNA would produce no signal. When concentrations of cylinder ranging from 0 to 100 
µM were examined with DNA, the LD signal produced confirmed the cylinder’s binding 
to DNA was specific. Furthermore, the DNA signal produced by the bases was 
  
42 
 
significantly decreased in the presence of very low cylinder concentrations.
49
 This could 
be attributed to an increased flexibility of the DNA molecule. Alternatively a shortening 
of DNA via bending, kinking, aggregation or compaction of the molecule may also be 
responsible.
68
 However, as the CD spectra has confirmed the DNA structure is 
maintained and preserved upon cylinder binding, it suggests that DNA is not being 
shortened due to kinking.
49 
         
 
The binding of these cylinders to linear plasmid DNA has been imaged at the molecular 
level using atomic force microscopy. The majority of images obtained using this 
technique for metal compounds bound to DNA have been restricted to covalent binders 
such as cisplatin.
49
 When in contact with low concentrations of cylinder, an increase in 
the number of bends and mean bend angle of DNA was observed in comparison to that 
seen with free DNA. More remarkable was the induction of intramolecular coiling, 
producing short coils of DNA that occurred with moderate concentrations of cylinder 
(Figure 1.30). The exact dimensions of the cylinder are crucial factors in the coiling 
process with an increase in size by 10 % causing a great reduction in the extent of coiling 
of DNA.
49
  
 
When the cylinder was crystallized with a palindromic hexanucleotide, a second mode of 
binding was uncovered. The crystal structure showed the cylinder to be located at the 
center of a DNA 3-way junction (Figure 1.31).
69
 This is feasible as palindromic sequence 
hydrogen-bonding (Watson-Crick) can be fulfilled via 3-way junctions, duplex structures 
or other junction structures including 4-way junctions. At the 3-way cylinder junction, the 
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DNA has a similar structure to DNA in junctions crystallized with proteins. In addition, 
the cylinder in the junction almost precisely overlaps with the crystal structure of free 
cylinder. This verifies that neither structure is significantly disturbed by the binding.
32
 
 
 
Figure 1.30. AFM images showing the dramatic intra-molecular coiling induced by the 
cylinders. Taken from ref 68.
 
 
Figure 1.31. Recognition of the centre of a 3-way DNA junction by a supramolecular 
cylinder. Taken from ref 70. 
 
The perfect fit of the cylinder binding to 3-way junctions is unlike any other known 
DNA-interacting molecule. Despite being less studied than 4-way (Holliday) junctions, 3-
way junctions are of interest as the replication fork is a type of Y-shaped junction. 
Therefore, whenever the DNA helix is unwound to replicate or transcribe DNA, a Y-
shaped, 3-way junction is formed.
71
 In cancer cells, DNA replication and transcription 
occurs at a much faster rate when compared to normal cells. Therefore a compound that 
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can recognize this particular structure of DNA and interfere with the replication of DNA 
has the potential for clinical applications.
69 
 
3-way junctions are also believed to occur in triplet repeat expansions present in unstable 
genomic DNA associated with the development of diseases including Huntington’s. 
These cylinders may therefore have potential therapeutic effects in these cases due to 
their ability to bind to 3-way junctions and stall the replication fork. Gel electrophoresis 
studies have shown that the cylinders can also recognize 3-way junctions with unpaired 
nucleotides.
72
 The ruthenium (II) and iron (II) cylinders have been shown to be active 
against certain cancer cells with a similar potency to cisplatin. It is not known how 
normal cells compare to cancer cells when treated with these compounds as this has not 
been investigated.   
 
Interactions of enantiomers of the iron cylinder have been examined to understand the 
mode in which this compound binds to DNA. The P-enantiomer is the positively twisted 
right-handed helicate and the M-enantiomer is the negatively twisted left-handed version 
(Figure 1.32). Earlier data showed that both caused the DNA to bend significantly. It has 
been found that they also cause considerable unwinding of the DNA helix with the        
M-enantiomer being much more effective at doing this. In addition, the M-enantiomer 
preferentially binds to normal sequences of alternating purines and pyrimidines.
73 
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Figure 1.32. The structures of the M-enantiomer (left) and P-enantiomer (right) of Iron 
cylinder. Iron atoms: purple, nitrogen: yellow, carbon atoms in three ligands: red, green 
and blue. Taken from ref 74. 
 
Maintenance of telomere length is one of the important features of tumour development 
which makes telomere quadruplexes an anticancer target. Recently, metal complexes 
were investigated for their ability to stabilize G-quadruplexes. The P-enantiomer of iron 
cylinder was proposed to prefer G-quadruplex over double stranded helical DNA 
although this is proposed to be related to the loops above the quadruplexes. Furthermore, 
telomeric G-quadruplexes were stabilized and transformed from antiparallel to hybrid 
structures if sodium was present in the environment.
74 
 
Recently, cell growth inhibition was used as an endpoint to assess the potency of the 
cylinder in comparison to cisplatin. The mitochondrial enzyme function was assessed and 
used to calculate IC50 values for both drugs against a range of tumour cell lines. Results 
showed cisplatin to be a more potent inhibitor of cell growth. However, the IC50 of 
cisplatin as assessed via the MTT assay was found to be 5 times greater than that of 
cylinder.  Both drugs were found to be effective at stopping cell growth but the results 
indicated that they operated via different mechanisms of action. The researchers 
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highlighted that the IC50 values obtained for the cylinder were similar to those for 
carboplatin which is used as alternative to cisplatin in cancer patients as it is less toxic 
and causes less undesirable effects (see section 1.5).
63
 
  
The iron cylinder’s ability to induce mutations was assessed by the Ames test. The Ames 
test is a bacterial mutagenicity assay used specifically to identify chemicals that cause 
genetic damage leading to mutations.
75
 Results showed no evidence of frameshift or base 
pair mutations occurring in bacteria as a result of cylinder treatment. The Comet assay 
was also employed to investigate the cylinder’s genotoxic potential in mammalian cells.  
This is a single cell gel electrophoresis assay which allows single and double strand 
breaks to be detected. Concentrations of iron cylinder ranging between 0 and 25 µM were 
investigated over a 24 hour period. The results showed no evidence of DNA strand 
breaks in breast, ovarian and leukemic cell lines.
63 
The results for the alkaline Comet 
assay provided evidence for the mechanism by which the cylinder was acting indicating 
that it was not directly inducing DNA strand breaks and therefore not directly genotoxic. 
The iron cylinder therefore has a significant advantage over cisplatin as it is able to stop 
cell growth and do so in the absence of genotoxicty and mutagenicity.
63
    
 
Investigating the effect of iron cylinder on the cell cycle in the HL60, myeloid leukemia 
cell line, revealed a significant arrest in the G0/G1 phase together with a reduced number 
of cells entering the S phase upon cylinder treatment (10 µM for 24 hours). These results 
provide supporting evidence for the cylinder’s ability to stop cells from entering the 
growth phase and reducing DNA synthesis. Programmed cell death, apoptosis occurred in 
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both adherent cell lines and HL60s when treated with 25 µM cylinder. This is consistent 
with the cylinder binding to the DNA and is further supported by evidence from flow-
cytometry and cell-cycle based assays showing a decrease in propidium iodide staining in 
cells.
63
 It is believed that the cell cycle arrest is due to non-covalent interactions with the 
DNA helix and through the use of two independent assays, researchers have been able to 
show that the mechanism by which the iron cylinder induces its effect is apoptosis as 
opposed to inflammatory necrotic cell death which disrupts surrounding viable tissues.
63
 
 
The exact mechanism of iron cylinder’s activity on the molecular level is yet to be 
investigated but so far research in several tumour cell lines has indicated that it works in a 
different way to cisplatin. As it is known that the cylinder interacts non-covalently with 
DNA, it has been hypothesized that its mechanism of action may involve it binding to 
and inhibiting replication forks which are a type of 3-way DNA junction. The potential 
ability of iron cylinder to stall the replication fork, inhibiting progression of the cell cycle 
and induce apoptosis in the absence of genotoxicity, puts it forward as a promising 
anticancer therapeutic.
76 
However, due to its lack of fluorescence, the iron cylinder 
cannot easily be imaged using fluorescence microscopy in cells. Although the fluorescent  
ruthenium analogue shows strong anticancer activity,
63
 it is difficult to synthesize and 
there is a need to create a much more fluorescent iron cylinder and develop indirect 
imaging methods. This will improve our understanding of the cellular fate and activity of 
iron cylinder. 
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1.9 Aims of the Thesis 
The aims of this thesis were to develop novel methods to investigate the localization, 
distribution and mechanism of action for the novel potential chemotherapeutic, iron 
cylinder. A breast cancer cell line (MDAMB-231), an ovarian cancer cell line (SKOV3) 
and a leukemic cancer cell line (HL60) were investigated with regards to their sensitivity 
to the cylinder. Novel methods of imaging non-fluorescent cylinder were developed. The 
cylinder’s genotoxic potential was investigated and compared to that of classic 
chemotherapeutics including cisplatin and etoposide in leukaemia cells. A goal of this 
thesis was to pioneer the first in vivo research relating to the iron cylinder by further 
exploring its effects in embryos of the model organism, Danio rerio (zebrafish). 
Specifically, the following areas were investigated:  
 
 Visualize Hoechst quenching through fluorescence microscopy in cancer cells 
 Quantify Hoechst quenching through fluorimetry / flow cytometry in cancer cells 
 Investigate the effect of increasing cylinder concentrations on the extent of 
Hoechst quenching in cancer cells 
 Compare sensitivity to cylinder across a range of cancer cell types    
 Confirm if 20 minutes of cylinder treatment is sufficient time for cylinder to gain 
access to DNA  
 Study the cylinder’s interaction with other fluorescent probes 
 Visualize quenching of nuclear GFP by iron cylinder in breast cancer cells using 
fluorescence microscopy   
 Quantify GFP quenching through fluorimetry in breast cancer cells 
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 Identify a therapeutic window over which the cylinder can bring about its effects 
in zebrafish embryos  
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CHAPTER 2 
 
 
Methods and Experimental Details 
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2.1 Compound Synthesis  
2.1.1 Synthesis of Ligand   
All chemicals were purchased from Sigma Aldrich (UK) and used without further 
purification. Ligand, (N,N’-bis(pyridin-2-ylmethylene)-4,4‟-diaminodiphenylmethane), 
was synthesized by combining 4,4‟-methylenedianiline (1.56 g, 8.00 mmol) and 
pyridine-2-carboaldehyde (1.40 ml, 15 mmol) in 50 ml ethanol. The solution was left to 
stir overnight and the resulting yellow precipitate filtered and recrystallised from ethanol. 
Yield: 65 % 
 
1H NMR (CD2Cl2): δ 8.72 (2H, d, J = 3.9 Hz, H6), δ 8.62 (2H, s, Him), δ 8.23 (2H, d, J 
= 8.1 Hz, H3), δ 7.85 (2H, t, J = 7.5 Hz, H4), δ 7.41 (2H, t, J = 7.0 Hz, H5), δ 7.30 (8H, 
m, Ha/b), δ 4.09 (2H, s, CH2).  
ESI MS: m/z 399 [(C25H20N4) + Na]
+
. 
 
2.1.2 Synthesis of Iron Cylinder 
1
 
The synthesized ligand (1.36 g, 0.003 mol) and Iron (II) chloride tetrahydrate (0.48 g, 
0.002 mol) was added to 200 ml methanol in a round bottom flask. The solution was 
refluxed for 3 hours, rotary evaporated, re-dissolved and precipitated with diethyl ether. 
Yield: 85 % 
 
1H NMR (MeOD): δ 9.21 (2H, s, Him), δ 8.75 (2H, d, J = 7.0 Hz, H3), δ 8.51 (2H, t, J = 
6.5 Hz, H4), δ 7.90 (2H, t, J = 6.1 Hz, H5), δ 7.49 (2H, d, J = 4.2 Hz, H6), δ 7.08 (4H, s, 
Ha/b), δ 5.62 (4H, s, Ha/b), δ 4.08 (2H, s, CH2).  
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ESI MS: m/z 310 [Fe2(C25H20N4)3]
4+
.  
 
Synthesis of iron cylinder was carried out every three months with the purity and stability 
being confirmed by CHN and NMR analysis prior to solutions being prepared. Sterile 
PBS was added to prepare a 5 mM stock solution of iron cylinder which was prepared 
fresh prior to use in assays.  
 
2.2 Cell Culture 
2.2.1 Cell Lines 
SKOV3, human caucasian ovary adenocarcinoma (91091004), MDAMB-231, human 
caucasian breast adenocarcinoma (92020424) and HL60, human caucasian promyelocytic 
leukaemia (98070106) cell lines were obtained from ECACC (European Collection of 
Cell Cultures). Luciferase-expressing MDAMB-231 (AKR-231) and GFP-expressing 
MDAMB-231 (AKR-201) cell lines were obtained from Cell Biolabs, Inc. These stable 
cell lines were created by having luciferase or GFP introduced by either lentivirus 
transduction or plasmid transfection, followed by selection of stable clones. 
  
MDAMB-231 and SKOV3 were chosen as previous work investigating the iron cylinder 
has used these two cell lines which represent commonly occurring cancers in women. It 
was important to compare the cylinder’s effects between adherent and suspension 
suspension cells and so the HL60 leukemia cell line was chosen for this purpose.      
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2.2.2 Complete Media Preparation 
GIBCO® RPMI (Roswell Park Memorial Institute) Media 1640 and GIBCO® DMEM 
(Dulbecco’s Modified Eagle Medium) were supplemented with foetal bovine serum, FBS 
(10 % v/v), penicillin (100 U/ml), streptomycin (100 µg/ml) and L-glutamine (2 mM). 
Complete media was stored in the fridge.  
 
2.2.3 Starting Cell Cultures 
SKOV3 and HL60 cell lines were cultured using complete RPMI media and MDAMB-
231 cell lines were cultured in complete DMEM. The cell lines were removed from liquid 
nitrogen storage and thawed in a 37 °C water bath. Complete media was also warmed in a 
37 °C water bath. Each cell line (1 x 10
6
 cells/ml) was added to 15 ml of fresh complete 
media in a 75 cm
3
 tissue culture flask with a vented cap (T75) (Costar). Cultures were 
incubated at 37 °C in a 5 % CO2, 95 % air incubator (Sanyo, MCO-17A). Media was 
changed every 2 days and cells were passaged every 3 or 4 days. 
 
2.2.4 Passage of Cells  
Once cells were confluent, they were passaged. Complete media, trypsin- EDTA 
(GIBCO®) and 0.01 M phosphate buffered saline, (PBS) (Sigma-Aldrich) were warmed 
in a 37 °C water bath. For MDAMB-231 cell lines and SKOV3 cells, the old media was 
carefully removed from the flask and 10 ml of PBS was added. The flask was tilted to 
ensure the entire surface had been covered. This was then removed and 2 ml trypsin 
added to the flask. The flask was placed in an incubator for 3 minutes. Flasks were 
checked under the microscope to ensure the cells had detached (flasks were tapped to 
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encourage the cells to detach). Fresh media (8 ml) was added to inhibit the trypsin and 
the contents of the flask were transferred to a 15 ml falcon tube. The cell suspension was 
centrifuged (Rotofix 32, Hettich Zentrifugen, Germany) for 5 minutes at 1000 rpm at 
room temperature and the supernatant discarded. Cells were resuspended in 1 ml of fresh 
media. To ensure a 1 to 5 passage, 200 µl of cell suspension was added to 15 ml of fresh 
media in a new T75 flask. HL60 cells were split by removing 10 ml of cell suspension 
from the T75 flask and adding the same volume of complete RPMI.  
 
2.2.5 Cryopreservation of Cells  
Confluent SKOV3 and MDAMB-231 cells from a T75 were cryopreserved to ensure a 
stock of viable cells was maintained. The old media was removed and cells were 
trypsinized and centrifuged to produce a pellet as described in section 2.2.4. The pellet 
was resuspended in 3 ml freezing medium (FBS containing 10 % v/v DMSO) and 1 ml 
aliquots transferred into 3 cryovials (Nunc). The name, date and cell type was clearly 
labeled. They were stored overnight in a -80 °C freezer and then transferred to vapour 
phase liquid nitrogen for long term storage. HL60 cells were transferred to a 15 ml falcon 
tube and centrifuged for 5 minutes. The supernatant was discarded and the cells 
resuspended in freezing media as for the other cell types. 
 
2.2.6 Maintenance of Cell Cultures (in T75 flasks) 
Cell cultures were maintained in T75 flasks containing 15 ml fresh media. These flasks 
were placed in a humidified incubator at 37 °C and 5 % CO2. The flasks were examined 
daily under the microscope for signs of contamination and general cell morphology. 
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Every 2 days, the old media was removed from the T75 flask. PBS (10 ml) was added to 
the flask and removed to eliminate any dead cells. Complete media (15 ml) was then 
added to the flask and the flask placed back in the incubator.  
 
2.2.7 Cell Counting  
A Neubauer haemocytometer was used to count cells. After the cells were trypsinized and 
centrifuged, the pellet was resuspended in 1 ml media (as described in section 2.2.4). 10 
µl of this cell suspension was added to 90 µl of fresh media in an eppendorf, creating a 
1:10 dilution. The diluted cells (20 µl) were then pipetted under the coverslip placed on 
top of the haemocytometer slide. The slide was viewed under a microscope and cells 
present in the central grid of the device were counted. Cells within two edges of the 
central square were also counted to take into account any cells on the borders. The 
number of cells/ml was calculated using equation 1. 
 
Equation 1. Cell density (cells/ml) = Number of cells counted x dilution factor (10) x 10
4 
 
2.3 MTT Reduction Assay 
2.3.1 Evaluating Cytotoxic Effects of Hoechst and Iron Cylinder Treatment  
Confluent SKOV3 and MDAMB-231 cells maintained in a T75 flask were trypsinized and 
centrifuged as described in section 2.2.4. The supernatant was discarded and the pellet 
was resuspended in 1 ml complete media. The cells were counted using a Neubauer 
Haemocytometer and seeded into 96 well plates at 1 x 10
4
 cells/well. Plates were left in 
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the incubator at 37 °C and 5 % CO2 for 24 hours to ensure they were confluent for 
treatment the following day.  
 
Following incubation, the media was carefully removed and each well was washed with 
PBS (warmed to 37 °C). Cells were then treated with Hoechst (2.5 µg/ml) for 20 minutes 
and then with iron cylinder (0, 10, 25, 35, 50 or 100 µM, repeated in triplicate). Once 
treated, cells were incubated (5 % CO2) for 20 minutes at 37 °C. Following incubation, 
each well was washed with 100 µl of PBS and 100 µl of complete media was added. The 
MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) solution was 
prepared in PBS (5mg/ml). The plates were incubated for 3 hours (37 °C, 5 % CO2) with 
50 µl MTT solution being added to each well. Following incubation, the media was 
removed from each well and 100 µl of DMSO was added to solubilise the purple 
formazan product. DMSO (100 µl) was also added to three empty wells to serve as a 
blank. The plate was read using a plate reader at an absorbance setting of 540 nM (BIO-
TEK, FL600, with KC
4
 software). The percentages of viable mitochondria were 
calculated using the average absorbance of the three readings (DMSO blank adjusted, 
with the control set to 100 %). A similar procedure was carried out for HL60 cells in 
eppendorf tubes. After cylinder treatment, cells were centrifuged (1000 rpm, 4 minutes), 
washed with PBS and the pellet resuspended in media containing MTT. Following 3 
hours of incubation, cells were centrifuged, the media was removed and replaced with 
100 µl DMSO. Samples were transferred to a 96-well plate and read using the plate 
reader as described above.      
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2.3.2 Evaluating Cytotoxic Effects of ATP and Luciferin with Iron Cylinder 
Treatment  
Confluent MDAMB-231 and luciferase-expressing MDAMB-231 cells maintained in a 
T75 flask were trypsinized and centrifuged as described in section 2.2.4. The cells were 
seeded into 96 well plates at 1 x 10
4
 cells/well and incubated for 24 hours as described in 
section 2.3.1. Following incubation, the media was carefully removed and each well was 
washed with PBS (warmed to 37 °C). Cells were incubated (5 % CO2) with iron cylinder 
(0, 10, 25, 35, 50 or 100 µM final concentration in final volume of 100 µl, repeated in 
triplicate) for 20 minutes. Following incubation, each well was washed with 100 µl of 
PBS and 100 µl of complete media was added. Cells were then treated with ATP and 
luciferin (final concentration of 1 mM for each in final volume of 100 µl). Following 
treatment, the plates were incubated with MTT using the procedure described in section 
2.3.1 and mitochondrial viability was calculated in the same way. 
 
2.4 Live Cell Fluorescence Imaging via Epifluorescence Microscopy 
SKOV3, MDAMB-231 and HL60 cells were grown in 50 mm MatTek glass bottom petri 
dishes (seeded at 1.5 x 10
5
 cells/well). After a 24 hour attachment period for SKOV3 and 
MDAMB-231, cells were preincubated with 2.5 µg/ml Hoechst 34580 in 3 ml culture 
medium for 20 minutes. Cells were then treated with iron cylinder for 20 minutes and 
imaged using a Nikon Eclipse Ti epifluorescence microscope (100x objective). 
Fluorescent and brightfield images were acquired before and after the treatment period. 
To prevent photobleaching, the laser was turned off following image capture. The 
samples were maintained at 37 °C by means of a heated stage.  
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2.5 Live Cell Fluorescence Imaging via Confocal Microscopy 
GFP-expressing MDAMB-231 cells were grown in 50 mm MatTek glass bottom petri 
dishes (seeded at 1.5 x 10
5
 cells/well). Cells were incubated for a 24 hour attachment 
period at 37 °C. Cells were viewed under the Leica DM IRE2 (63x objective) confocal 
system and nuclei were identified by focusing in the Z-plane. Cells were then treated with 
iron cylinder for 20 minutes, imaged and fluorescent/ brightfield images were acquired 
before and after the treatment period. To prevent photobleaching, the laser was turned off 
following image capture. The samples were maintained at 37 °C by means of a heated 
stage.  
 
2.6 Quantifying Fluorescence Quenching via Fluorimetry and Flow Cytometry 
Confluent SKOV3 and MDAMB-231 cells maintained in a T75 flask were trypsinized and 
centrifuged as described in section 2.2.4. The supernatant was discarded and the pellet 
was resuspended in 1 ml media. The cells were counted using a Neubauer 
Haemocytometer and seeded into 6 well plates at 1.5 x 10
5
 cells/well. Plates were left in 
the incubator (37 °C, 5 % CO2) for 24 hours to ensure they were confluent for treatment 
the following day. HL60 cells were used immediately after being seeded into wells (1.5 x 
10
5
 cells/well) as there was no need for attachment in this cell type. 
 
MDAMB-231 and SKOV3 cells in the 6 well plates were trypsinized and centrifuged. 
HL60 cells were centrifuged and washed with PBS. Each pellet was resuspended in 1ml 
complete media containing 2.5 µg/ml Hoechst 34580 for 20 minutes at 37 °C. The iron 
cylinder was then added followed by a further 20 minute incubation at 37 °C. The 
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fluorescence of 200 µl of each sample was measured using a TECAN GENios 
Multifunction Microplate reader (λexc = 340 nm, λem = 460 nm). The remaining 800 µl of 
each sample was transferred to a FACS tube and 10,000 events counted using the BD 
FACS Aria Cell-Sorting System. Fluorescent cells (λexc = 340 nm, λem = 460 nm) were 
gated to eliminate the debris from the whole-cell population. Hoechst fluorescence was 
presented as a histogram with a distinct peak. The median value for each histogram was 
obtained and used in analysis. Three repeats were present at each concentration of iron 
cylinder used (0, 10, 25, 35, 50 and 100µM). 
 
2.7 ToxiLight Assay 
The ToxiLight assay is a bioluminescent, non-destructive cell lysis assay kit which 
measures the release of the enzyme, adenylate kinase from damaged cells into the 
surrounding media. 
 
MDAMB-231 cells were seeded into 96-well plates at 1x10
4
 cells/well. Cells were 
treated with iron cylinder (0, 10, 25, 35, 50 or 100 µM in final volume of 100 µl) with 3 
repeats present for each concentration tested. The plates were incubated for 20 minutes at 
37 
0
C. Cell supernatant (20 µl) was transferred to a white-walled 96-well plate and 100 µl 
of adenylate kinase detection reagent was added to each sample. The plates were left to 
stand for 5 minutes for signal generation and the emitted light intensity was measured 
using a plate reader (TECAN GENios multifunction microplate reader). Positive control 
samples were present where cells were treated with a 100% lysis buffer and negative 
controls where no treatment or detection reagent was used.  
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The cylinder’s ability to interfere with the ToxiLight kit was confirmed using whole cell 
lysate. A confluent T75 flask containing MDAMB231 cells was treated with lysis reagent 
(100 %) for 5 minutes at 37 
0
C. Aliquots of media (20 µl) were removed from the flask 
and transferred to a 96-well plate. Each well was then treated for 20 minutes with iron 
cylinder (0, 10, 50, 100 or 150µM) and 100 µl of adenylate kinase detection reagent was 
added to each well. Emitted light intensity was measured using the same procedure 
described above with each concentration of iron cylinder being tested in triplicate.   
 
2.8. Investigating Inhibition of Luciferase by Iron Cylinder 
The assay was carried out in a 96-well luminescence plate in the absence of cells. To 
bypass the first step of the ToxiLight assay, an excess of ATP was added to each well (1 
mM). Concentrations of iron cylinder were then added (0, 10, 25, 35, 50 or 100 µM) 
keeping the final volume in each well at 20 µl. This was followed by 100 µl of adenylate 
kinase detection reagent in each well. Plates were incubated for 5 minutes before reading 
the luminescence. Each concentration was tested in triplicate. The synthesized ligand, it’s 
components (4,4‟-methylenedianiline and pyridine-2-carboaldehyde) and iron (II) 
chloride tetrahydrate were also investigated for their role in luciferase inhibition. Each 
compound was made up in solution to the same concentration as present in the 
synthesized cylinder at each of the concentrations of cylinder tested. Each compound was 
examined using the method described above for iron cylinder. The chelating ligands: 
2,2’-bipyridine and 1,10’-phenanthroline were also tested using the same method.   
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2.9 Quantifying Luminescence Production in MDAMB-231 Cells Stably Expressing 
Luciferase 
MDAMB-231 and luciferase-expressing MDAMB-231 cells
2,3
 were seeded into 96 well 
luminescence plates and incubated for 24 hours as described in section 2.3.2. ATP and 
luciferin were added to each well (1 mM for each in final volume of 100 µl) prior to 
recording luminescence. Emitted light intensity was measured using a plate reader 
(TECAN GENios multifunction microplate reader). Luminescence production was 
quantified over time using the same method where emission was recorded at 3 minute 
intervals over a 30 minute period. 
 
2.10 Investigating Iron Cylinder’s Inhibition of Luminescence in Luciferase- 
Expressing MDAMB-231 Cells   
Confluent T75 flasks containing MDAMB-231 and luciferase- expressing MDAMB-231 
cells were treated with lysis reagent (100 %) for 5 minutes at 37 
0
C. Aliquots of media 
(20 µl) were removed from each flask and transferred to a 96-well plate. Each well was 
then treated with iron cylinder (0, 10, 25, 35 50 and 100µM) for 20 minutes at 37 
0
C. 
ATP and luciferin were supplied (1 mM for each in final volume of 100 µl) prior to 
recording luminescence. A negative control was also present for each cell type where 
substrates were not provided before the luminescence recording. Each concentration of 
iron cylinder was tested in triplicate. The luminescence values shown in the results were 
calculated using the average of three readings. Emitted light intensity was measured 
using a plate reader (TECAN GENios multifunction microplate reader).  
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Trypsinized cells were also investigated where cells were seeded into 96 well plates as 
described in section 2.3.2. Following the 24 hour incubation, the media was carefully 
removed and each well was washed with PBS (warmed to 37 °C). Cells were then 
trypsinized where 30 µl trypsin was added to each well for 5 minutes at 37 °C. Trypsin 
was inhibited by adding 100 µl complete media to each well. Cells were then transferred 
to eppendorfs and centrifuged (1000 rpm, 4 minutes), washed with PBS and the pellet 
resuspended in 1 ml complete media treated with iron cylinder as described above. 
Following incubation, cells were centrifuged, washed with PBS and transferred to a 96-
well luminescence plate. ATP and luciferin were supplied and the light emission 
quantified in the same way as described above. Adherent cells were also investigated 
using a similar procedure in 96 well plates. Following the 24 hour incubation period 
needed for cells to attach, cells were washed and treated with iron cylinder in the same 
way. Cells were then washed with PBS and treated with ATP and luciferin prior to 
recording luminescence as described above. 
 
2.11 Investigating Quenching of Purified GFP by Iron Cylinder 
Purified GFP in solution (250 µg/ml) was purchased from Applied Biological Materials 
Inc. The assay was carried out in a 96-well fluorescence plate in the absence of cells. 
GFP (0.5 µM in final volume of 100 µl) was added to distilled water. Each well was 
treated with concentrations of iron cylinder (0, 10, 25, 35, 50 and 100 µM in final volume 
of 100 µl) for 20 minutes at 37 
0
C for each incubation period. The fluorescence of 
purified GFP was measured using a fluorimeter (TECAN GENios multifunction 
microplate reader) (λexc = 485 nm, λem = 530 nm). Three repeats were collected at each 
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concentration of iron cylinder tested and the data was blank adjusted to remove 
background fluorescence of cylinder alone for each of the concentrations investigated. 
 
2.12 Investigating GFP Quenching by Iron Cylinder in MDAMB-231 Cells Stably 
Expressing GFP 
GFP-expressing MDAMB-231 cells
1, 2
 were seeded into a 96 well fluorescence plate at 1 
x 10
4
 cells/well as described in section 2.2. The plate was left in the incubator at 37 °C 
and 5 % CO2 for 24 hours to ensure cells were confluent for treatment the following day. 
Following incubation, the media was carefully removed and each well was washed with 
PBS (warmed to 37 °C). Cells were treated with iron cylinder and the fluorescence 
recorded as described in section 2.11. The data was blank adjusted using fluorescence 
values obtained from non-expressing MDAMB-231 cells treated with concentrations of 
cylinder in the same way. 
 
2.13 Investigating Hoechst Quenching by Iron Cylinder in GFP-Expressing 
MDAMB-231 Cells  
MDAMB-231 and GFP-expressing MDAMB-231 cells were seeded into 96 well 
fluorescence plates and incubated for 24 hours in the same way as described in section 
2.12. Cells were washed with PBS prior to incubation with 2.5 µg/ml Hoechst 34580 for 
20 minutes at 37 °C. Cells were then treated with concentrations of iron cylinder (0, 10, 
25, 35, 50, 100 µM) for 20 minutes at 37 
0
C. Cells were washed with PBS prior to 
recording fluorescence. Each concentration of iron cylinder was tested in triplicate. The 
fluorescence was recorded in the same way as described in section 2.11. The data was 
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blank adjusted using fluorescence values obtained from cells treated with concentrations 
of cylinder alone. 
 
2.14 Comparing the Intensity of Fluorescence Quenching between Hoechst and GFP 
in GFP-Expressing MDAMB-231 Cells  
GFP-expressing MDAMB-231 cells were seeded into a 96 well fluorescence plate at 1 x 
10
4
 cells/well as described in section 2.2. The plate was left in the incubator at 37 °C and 
5 % CO2 for 24 hours to ensure cells were confluent for treatment the following day. 
Cells were washed with PBS prior to incubation with 2.5 µg/ml Hoechst 34580 for 20 
minutes at 37 °C. Cells were then treated with 50 µM iron cylinder for 20 minutes at     
37 
0
C. Cells were washed with PBS. Two experiments were set up. In the first, the 
cylinder treatment was washed away and the fluorescence recorded at 20 minute intervals 
over 3 hours (λexc = 340 nm, λem = 460 nm for Hoechst, λexc = 485 nm, λem = 530 nm for 
GFP) using a fluorimeter (TECAN GENios multifunction microplate reader). The data 
was adjusted using fluorescence values obtained from cells treated with cylinder alone. 
The average fluorescence of three readings was used for each time point investigated. In 
the second, the cylinder treatment was not washed away and left in contact with the cells 
for the duration of the experiment. The fluorescence was recorded similarly to the first 
experiment.  
 
2.15 In Vivo Toxicity Studies 
Zebrafish embryos at one-cell stage were injected using an injection needle pulled from 
borosilicate glass micro-capillary (with Fillament, OD 1.0 mm, ID 0.78 mm, Harvard 
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Apparatus) on P-97 Flaming/Brown Micropipette Puller (Sutter Instruments). The 
injection were performed by hand using a MINJ-1 microINJECTOR(tm) System (Tritech 
Research) under Nikon SMZ660 Zoom Stereo Microscope. Each embryo was injected 
with 1.5-2 nl injection solution supplemented with 0.1 % Phenol Red (Sigma) as injection 
marker. 
 
Following injection the embryos were maintained at 28 °C in E3 media, supplemented 
with 50 microgram per ml gentamicin (Fisher) to prevent bacterial and fungal growth. E3 
media consisted of 5.0 mM NaCl, 0.17mM KCl, 0.33mM Ca2Cl, 0.33mM MgSO4, 
2.3mM NaHCO3 and had a pH of 7.4. Embryos were injected with 10 or 100 µM 
compound and survival was quantified by counting live embryos at 4 and 24 hours post 
fertilization (hpf). The percentages of viable embryos shown in the results were 
calculated using the average count of three experiments. 
 
2.16 In Vitro Genotoxicity Studies 
2.16.1 Alkaline Comet Assay 
Confluent HL-60 cells maintained in a T75 flask were centrifuged as described in section 
2.2. The supernatant was discarded and the pellet was resuspended in 1 ml media. The 
cells were counted using a Neubauer Haemocytometer and seeded into 6 well plates at 
1.5 x 10
5
 cells/well. Cells were treated with each compound for 8 hours at 37 °C.  
Following treatment, cells were transferred to eppendorfs and centrifuged at 1000 rpm for 
4 minutes. Cells were then washed twice with PBS before being resuspended in 150µl of 
PBS. 15µl of the re-suspended cells was transferred to a sterile eppendorf containing 300 
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µl molten 2% low melting point agarose (LMPA). This cell suspension (150µl) was then 
transferred to a glass microscope slide pre-coated with 0.5 % normal melting point 
agarose (NMPA). A glass cover slip was then carefully placed on top of each slide. Slides 
were left to stand on a metal tray over ice and for approximately 20 minutes at 4 °C to 
allow the agarose to solidify. 
 
Coverslips were then removed and the slides were incubated for 1h at 4
º
 C in cold lysis 
buffer (2.5M NaCl, 0.1M Na2-EDTA, 10mM Tris base, 1% sodium N-lauryl sarcosinate, 
10% DMSO and 1% Triton X-100, pH 10).
4
 Following lysis, slides were placed in a 
horizontal electrophoresis tank filled with cold electrophoresis buffer (300mM NaOH and 
1mM Na2-EDTA) for 20min without electrophoresis and were then electrophoresed for 
20min (32V, 300mA). Slides were washed three times at five minute intervals using cold 
neutralization buffer (0.4 M Tris base, pH 7.5). Slides were then stained by adding 50µl 
SYBR gold (1 x solution) to each slide and carefully placing a cover slip over the top. 
Slides were stored in the dark at 4 °C overnight. Slides were examined with the 20 X lens 
using a Axiovert 10 inverted fluorescence microscope (Zeiss Ltd, Göttingen, Germany). 
Image analysis was carried out using the Comet 4.0 software program and 100 cells on 
each slide were randomly selected for analysis. The median percentage tail intensity was 
chosen to assess the extent of DNA damage. Median values obtained for 3 separate 
experiments were analyzed for each compound investigated.  
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2.16.2 Neutral Comet Assay 
The same procedure was followed as described for the alkaline comet assay (section 
2.16.1) using lysis buffer (146 mM NaCl, 30 mM Na2-EDTA, 1 mM Tris-HCL, 1% 
sodium N-lauryl sarcosinate, pH 9) and electrophoresis buffer (0.4 M Tris Base, pH 8.3).
4
  
 
2.17 Statistical Analysis of Data 
Statistical analysis of all the data was carried out using SPSS statistics 20. The data was 
tested for normal distribution using the Shapiro-Wilk test. If the data was found not to be 
normally distributed, non-parametric statistics were used (Kruskal Wallis test, Mann-
Whitney U test). Normally distributed data was tested for homogeneity of variances using 
Levene Statistic. If the data showed no homogeneity of variances, non-parametric 
statistics were used. For data showing homogeneity of variances, parametric statistics 
were used (One-way ANOVA with Post-hoc: Tukey test). 
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CHAPTER 3 
 
 
Hoechst Quenching as a Novel Method of Imaging the 
Non-Fluorescent Iron Cylinder  
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3.1 Introduction 
The ability of the iron cylinder to stall the replication fork, inhibit cell cycle progression 
and induce apoptosis in the absence of genotoxicity suggests its potential use in 
anticancer treatment.
1
 Research has been carried out to associate the cellular activity of 
the cylinder with its non-covalent methods of DNA-binding.
1
 Due to its lack of 
fluorescence, the iron cylinder cannot be imaged directly by fluorescence microscopy. 
Although the ruthenium analogue is fluorescent, it is difficult to synthesize and does not 
have strong fluorescence.
2
 To help improve our understanding of the cellular fate and 
activity of the iron cylinder, indirect methods of imaging the cylinder need to be 
developed. 
 
Fluorescence occurs when an atom or molecule that has absorbed a photon of a particular 
wavelength, emits a photon of another wavelength. During the absorption/emission 
process, some energy is shifted to vibration and rotation leading to a reduction in energy 
(increase in wavelength) of the light emitted. The shift between the maximum of the 
excitation and emission curves is known as Stokes’ shift. Fluorescent probes that have a 
very small Stokes’ shift have limited use in fluorescence imaging as the sensitivity of 
detection is limited due to an inability to accurately separate the excitation and emission 
light.
3 
Fluorophores can repeatedly undergo the fluorescence process which is very useful 
as a single fluorophore molecule can produce a signal many times. Therefore 
visualization of microscopic samples via fluorescence is an extremely sensitive method 
as very small concentrations of stain can be visualized.
4
 One potential problem is that 
fluorophores are vulnerable to degradation due to their structural instability during the 
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excited lifetime. The structure of the fluorophore may change due to illumination at high 
intensity. This process is known as photobleaching and the fluorophore no longer 
fluoresces.
4
 The use of fluorophores is necessary in fluorescence microscopy to observe 
structures of interest inside a specimen. For accurate measurements of fluorescence to be 
gained, the stain of choice should have stable fluorescence, be specific in its binding and 
be able to penetrate deep into tissue sections. Stains with distinct properties have been 
exploited for a diverse range of applications. There are three main classes of DNA stains. 
These are minor-groove binders (Hoechst and DAPI stains), intercalating dyes 
(propidium iodide and ethidium bromide) and other miscellaneous DNA stains (acridine 
orange).
4
   
  
Hoechst 34580, 33342 and 33258 are supravital cell membrane-permeable bisbenzimide 
dyes which bind to the minor groove of double stranded DNA with a preference for AT-
rich regions (4-5 base pairs in length) (Figure 3.1). Hoechst 33258 is less membrane 
permeable than 33342 although all three are relatively non-toxic and soluble in water. 
When bound to nucleic acids, Hoechst 34580 has a longer wavelength spectrum when 
compared to the other dyes. When excited by ultraviolet light (around 350 nm), they emit 
a cyan/blue fluorescence with an emission maximum around 461 nm. Hoechst stains are 
used for labeling in flow cytometry, fluorescence activated cell sorting and fluorescence 
microscopy.
 4 
Other fluorescent DNA stains include the blue nucleic acid stain, DAPI, 
which binds to the minor groove of DNA. DAPI (λexc = 358 nm, λem = 461 nm) binds 
double stranded DNA which causes a 20 fold increase in fluorescence intensity. This is 
believed to be caused by its protection from water when in minor groove of DNA.
4
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Unlike Hoechst, DAPI does not penetrate cell membranes and cannot be used to stain live 
cells. This makes the Hoechst the dyes of choice for live cell DNA staining.  
 
A            
 
B 
 
C 
 
D 
 
 
Figure 3.1. Molecular structures of Hoechst dyes (A) 34580 (B) 33342 (C) 33258 and 
(D) DAPI.  
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To enable longer lengths of DNA to be recognized, the structure of the dyes can be 
expanded.
5
 Two Hoechst 33258 moieties linked together were developed to recognize 
DNA with two A3T3 motifs. Due to the flexibility of the link, the molecule was able to 
bind to a separating DNA duplex with two A3T3 motifs. Despite this, it is also able to 
bind to a DNA 3-way junction where A3T3 motifs exist separately in two different arms.
6
 
 
Recently, the covalent binding anticancer trinuclear platinum drug, BBR-3464 was 
investigated. The Pt-DNA interstrand adducts formed by this drug were found to be 
different from those formed by the classic chemotherapeutic, cisplatin. Cytotoxicity 
studies revealed the drug’s uptake into ovarian cancer cell lines (SKOV3 and A2780) to 
be much greater than that of cisplatin. Kinetic analysis into the crosslinking occurring 
revealed changes in the AT pairs of the double helix which were consistent with pre-
association occurring in the minor groove of DNA. Competition binding studies between 
minor groove ligands and BBR-3464 were carried out. The Hoechst 33258 dye was used 
which binds in the minor groove of DNA with high affinity for sequences rich in AT 
regions (Figure 3.2). The strength of binding was analysed and results showed that the 
interaction of Hoechst with DNA was improved in the presence of BBR-3464 as 
identified by increased Hoechst fluorescence intensity. Structural analysis of the 
interaction between Hoechst and DNA revealed that an induced fit and a choice of 
conformation were involved in the process. The level of induced fit was influenced by 
conformational changes in the sugar-phosphate DNA backbone and changes in base step 
factors.
7
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Figure 3.2. Groove binding of Hoescht 33258 to the minor groove of DNA. Taken from 
ref 8. 
 
Fluorescence is commonly used in biochemistry to detect various compounds especially 
as an indicator in immunoassays. Fluorescence indicators provide many advantages 
including possible combination with dyes that have different excitations and emissions, 
highly sensitive measurements, availability of detection instruments and a range of 
markers that can be conjugated to reagents of interest.
9
 The process by which a 
molecule’s fluorescence intensity is reduced is referred to as fluorescence quenching. 
Fluorophore quenching can occur through a number of processes such as energy transfer, 
collision, formation of complexes and excitation reactions.
10
 The occurrence of dynamic 
or collisional quenching involves collision leading to production of a transient complex 
between a fluorophore in the excited state and a quencher in the ground state. Upon 
deactivation, the complex in the excited state dissociates, which results in both the 
fluorophore and quencher returning to the ground state. Diffusion controls the process of 
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dynamic quenching as the quencher has to diffuse to the fluorophore during its lifetime in 
the excited state. Furthermore, when a non-fluorescent complex is produced between a 
quencher and fluorophore in the ground state, the method is known as static quenching.
10
            
 
The commonly prescribed antibacterial drug, norfloxacin was recently investigated for 
fluorescence quenching by the metal ions, Mn
2+
 Cu
2+
, Co
2+
 and Ni
2+
. Results showed that 
when metal quenchers were added to a solution of norfloxacin, quenching took place 
even when very low concentrations were used. Quenching constants obtained were found 
to be much larger than would be expected with a diffusion- controlled mechanism of 
quenching. This was similar to values obtained for quenching constants of other closely 
related antibiotics. The results indicated that binding interactions were occurring between 
quencher and fluorophore as the constant value was beyond the limit of diffusion-
controlled mechanisms.
10
 The emitted fluorescence of the drug was reduced via 
formation of complex and collisional quenching. The large static and bimolecular 
quenching constants provided supporting evidence for strong orbital-orbital and ion-
dipole interactions between metal quenchers and norfloxacin. From the metal cations 
investigated, the electron scavenger, Cu
2+
 was found to be most efficient at quenching the 
fluorescence.
10
         
 
Recently studies were carried out to investigate the interactions of human serum albumin 
with the antipsychotic drug, chlorpromazine using fluorescent techniques. Researchers 
hoped to obtain information about the mechanism of quenching and fluorescence 
resonance energy transfer between chlorpromazine (Figure 3.3) and human serum 
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albumin. Spectral results showed a reduction in fluorescence intensity of the tryptophan 
in human serum albumin with increasing concentrations of the drug. As the emission 
wavelength of the tryptophan residue remained stable this suggested that the 
chlorpromazine/albumin interaction did not cause conformational changes in the 
protein’s structure. This research provided methods to study drug-protein interactions 
through the use of fluorescence techniques. Results found chlorpromazine to interact with 
the protein through both static and dynamic quenching mechanisms. This work was of 
important biological significance as albumin is a transporter for numerous clinical drugs 
and its interactions have not been well studied.
11 
 
Figure 3.3.  The structure of Chloropromazine. 
 
Changes to the transmembrane mitochondrial potential are often examined through the 
use of fluorescent probes. In a recent study, the fluorescent mitochondrial dye, 
MitoTracker Red CMXRos (Figure 3.4) was used to investigate the effect of the 
anticancer drug, adaphostin (Figure 3.5) on mitochondria in live cells as well as isolated 
mitochondria.
12
 The study aimed to confirm whether or not the drug interacted directly 
with the mitochondria. Through the use of an ion-selective electrode, adaphostin 
produced no effect on the transmembrane potential or on oxidative phosphorylation in 
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mitochondria. Despite this, the drug was found to interfere with membrane potential 
when fluorescent mitochondrial dyes were used.   
 
Figure 3.4. The structure of Mitotracker red.  
 
Adaphostin was initially found to decrease fluorescence of MitoTracker Red in both 
isolated mitochondria and live cells. This fluorescence quenching was similar to that 
observed by compounds well-known for their disruption of the mitochondrial membrane 
potential. However, further investigations provided evidence against adaphostin’s ability 
to directly affect the function of mitochondria. The drug did not cause cytochrome c 
leakage from the mitochondria. In addition, inhibitors of membrane potential did not 
prevent adaphostin –induced fluorescence quenching. Furthermore, using a non-
fluorescent ion-selective probe did not produce any drug-induced reduction in membrane 
potential. This data provided evidence for adaphostin-induced fluorescence quenching of 
MitoTracker Red being due to a direct interaction. Moreover, the addition of adaphostin 
to solutions containing fluorescent mitochondrial dyes resulted in a decreased 
fluorescence.
12
 This study highlights that caution should be taken when using fluorescent 
dyes to monitor changes in mitochondrial membrane potential.  
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Figure 3.5. The structure of Adaphostin.  
 
As the iron cylinder is not fluorescent, it is important to develop methods to image it 
indirectly. One potential method would be to investigate its ability to quench the 
fluorescence of the Hoechst molecule or displace it. It is known that the cylinder can 
quench Hoechst on DNA in vitro. It is assumed that occurs by Hoechst displacement 
from the minor groove when cylinder binds in close proximity in the major groove. In 
this chapter, iron cylinder’s ability to quench nuclear fluorescence from cells stained with 
Hoechst 34580 was investigated. In three different cancer cell types: SKOV3, MDAMB-
231 and HL60, epifluorescence microscopy was used to directly image changes in 
nuclear Hoechst fluorescence following treatment with iron cylinder. Flow cytometry 
was carried out to quantify changes occurring in the fluorescence of a large population of 
cells when treated with different concentrations of compound. 
 
3.2 Results and Discussion 
Their ability to act on DNA in a different way to cisplatin makes these metal cylinders a 
novel exciting group of agents. The iron cylinder not only binds to the DNA major 
groove but also fits into Y-shaped junctions including the fork junction important in 
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DNA replication. Its lack of fluorescence makes the iron cylinder difficult to image using 
fluorescence microscopy in cells. A focus for this thesis therefore, is to develop indirect 
ways of imaging this cylinder to identify its location in cells and help us to better 
understand its mechanism of action. 
 
It is known that iron cylinder has the ability to competitively displace ethidium and 
propidium from DNA in vitro.
13
 However, it can also displace other binders of DNA 
including Hoechst dyes.
14
 An initial study had described how HL60 myeloid leukemia 
cells were incubated with the Hoechst dye for 20 minutes prior to being treated with 
increasing concentrations of iron cylinder for 20 minutes. The cells were then collected, 
washed twice, resuspended in PBS and the fluorescence signal recorded. The results 
identified a concentration-dependent decrease in the Hoechst fluorescence signal with 
increasing concentrations of iron cylinder.
14
 This was consistent with the cylinder 
entering the cell nucleus, binding to the major groove of DNA and either displacing or 
quenching the Hoechst dye from the minor groove resulting in a decrease of nuclear 
fluorescence. This was the starting point for the work described in this chapter; which 
seeks to extend the work to investigate in more detail the cylinder’s ability to quench 
nuclear Hoechst 34580 fluorescence in adherent cell lines (SKOV3, human caucasian 
ovary adenocarcinoma, MDAMB-231, human caucasian breast adenocarcinoma) as well 
as non-adherent cell lines (HL60, human caucasian promyelocytic leukaemia). 
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3.2.1 Cytotoxicity  
To identify suitable non-toxic concentrations of cylinder and Hoechst for the 
experiments, cell viability was first assessed via an MTT assay. The MTT assay is a 
sensitive method of measuring the reductive function of mitochondria in cells and 
provides a measure of an endpoint related to cell viability. Metabolically active cells 
reduce the yellow tetrazolium MTT (3-(4, 5-dimethylthiazolyl-2)-2, 5-
diphenyltetrazolium bromide) by the action of dehydrogenase enzymes generating the 
purple product, formazan. This is then solubilised and quantified by spectrophotometric 
means. 
 
Mitochondrial MTT reduction was measured at five different concentrations of iron 
cylinder to determine non-toxic concentrations for treating SKOV3, MDAMB-231 and 
HL60 cells. The assay was carried out following treatment with Hoechst and then iron 
cylinder (20 minutes at 37 
0
C for each incubation period). The percentages of viable cells 
shown in the results were calculated using the average absorbance of three readings 
(DMSO blank adjusted) (Figure 3.6). The results show no significant reduction in the 
number of viable cells when treated with these concentrations of iron cylinder for these 
periods. Over 94% of SKOV3 and 98 % of MDAMB-231 and HL60 cells remained 
viable even when treated with the top concentration of 100 µM cylinder. Therefore, the 
MTT assay identified that concentrations at or below 100 µM would not significantly 
disrupt mitochondrial function which was used as an indicator of cell viability. Further 
evidence of viability was provided by assessing cell morphology at each of the 
concentrations tested. This involved visualizing the cells under the microscope to ensure 
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the membranes were intact and the cells were not showing any signs of stress. As a result, 
throughout this thesis, concentrations of 0, 10, 25, 35, 50 and 100 µM were selected for 
use in the assays.     
 
 
Figure 3.6. Evaluation of cytotoxic effects of Hoechst and Iron cylinder treatment in 
SKOV3, MDAMB-231 and HL60 cells using the MTT assay. Cells were treated with 
Hoechst (0.5 µg/ml) followed by treatment with iron cylinder for 20 minutes at 37 
0
C 
prior to measuring MTT reduction. Values are the mean of three separate experiments ± 
S.E.M. No significant difference from control (p>0.05 in SKOV3, MDAMB-231 and 
HL60 cells, One-way ANOVA).  
 
3.2.2 Investigating Fluorescence Quenching via Live Cell Fluorescence Imaging 
Live SKOV3, MDAMB-231 and HL60 cells grown in MatTek dishes were imaged by 
epifluorescence microscopy. Cells were pre-incubated with Hoechst for 20 minutes 
followed by treatment with 50 µM iron cylinder for 20 minutes. Brightfield and 
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fluorescent images were acquired at the start and end of the 20 minute cylinder treatment 
period with the laser turned off in between to prevent photobleaching. The fluorescence 
of the nucleus was monitored visually for changes. (Figures 3.7, 3.8 and 3.9). 
 
A Time: 0 minutes    Time: 20 minutes 
  
 
B Time: 0 minutes    Time: 20 minutes 
  
 
Figure 3.7. Epifluorescence imaging showing fluorescent and brightfield images of 
SKOV3 cells treated with Hoechst for 20 minutes followed by treatment with 50 µM iron 
cylinder (A) Fluorescent and brightfield images of untreated control SKOV3 cells imaged 
at the start and end of the 20 minute period (B) Fluorescent and brightfield images of 
SKOV3 cells imaged immediately after cylinder treatment and 20 minutes after cylinder 
treatment. 
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A Time: 0 minutes    Time: 20 minutes 
  
 
 
B Time: 0 minutes    Time: 20 minutes 
  
 
Figure 3.8. Epifluorescence imaging showing fluorescent and brightfield images of 
MDAMB-231 cells treated with Hoechst for 20 minutes followed by treatment with 50 µM 
iron cylinder (A) Fluorescent and brightfield images of untreated control MDAMB-231 
cells imaged at the start and end of the 20 minute period (B) Fluorescent and brightfield 
images of MDAMB-231 cells imaged immediately after cylinder treatment and 20 
minutes after cylinder treatment. 
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A Time: 0 minutes    Time: 20 minutes 
  
 
 
B Time: 0 minutes    Time: 20 minutes 
  
 
Figure 3.9. Epifluorescence imaging showing fluorescent and brightfield images of HL60 
cells treated with Hoechst for 20 minutes followed by treatment with 50 µM iron cylinder 
(A) Fluorescent and brightfield images of untreated control HL60 cells imaged at the 
start and end of the 20 minute period (B) Fluorescent and brightfield images of HL60 
cells imaged immediately after cylinder treatment and 20 minutes after cylinder 
treatment. 
 
Previous work had explored effects on a bulk cell population using fluorimetry on a 
suspension of HL60 cells in a cuvette. Now in this work, fluorescence microscopy was 
used to image changes occurring in the intensity of nuclear Hoechst fluorescence of live 
  
92 
 
cells following treatment with iron cylinder. This allows the effect on individual cells to 
be visualised directly.  
 
For each of the three cell types investigated, the results show a visual decrease in the 
fluorescence intensity of the nucleus at the end of each treatment period when compared 
to the untreated control cells (Figures 3.7, 3.8 and 3.9). This is consistent with the 
cylinder entering the nucleus and displacing Hoechst from the minor groove due its close 
proximity in the major groove. The results demonstrate that a non-fluorescent compound 
binding to the DNA can be indirectly imaged by its ability to quench another fluorescent 
molecule nearby. These results reflect changes taking place at a cellular level and any 
conclusions made can only be representative of the small number of selected cells in 
view. To quantify Hoechst quenching and investigate its occurrence in the entire sample 
population, flow cytometry and fluorimetry studies were undertaken. 
 
3.2.3 Quantifying Hoechst Fluorescence via Fluorimetry and Flow Cytometry 
Hoechst fluorescence for all three cell types at each cylinder concentration tested was 
measured. Adherent SKOV3 and MDAMB-231 cells were trypsinized and centrifuged 
and non-adherent HL60 cells were centrifuged. Cells were counted and pre-incubated 
with Hoechst 34580 for 20 minutes at 37 
0
C. This was followed by a further 20 minute 
incubation at 37 
0
C with concentrations of iron cylinder. 20 % of each sample was 
removed for analysis by fluorimetry (BIO-TEK, FL600, with KC
4
 software) which was 
used to record the fluorescence of the entire population present in each sample (λexc = 340 
nm, λem = 460 nm). 
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The remaining 80 % of each sample was analysed by flow cytometry. This involved 
suspending cells in a fluid stream and passing them through a light beam in single-file.  A 
BD FACSAria Cell-Sorting System was used to count 10,000 events using the Hoechst 
blue channel (λexc = 340 nm, λem = 460 nm). For each sample passing through the flow 
cytometer, a two-dimensional dot-plot was produced showing the distribution of 10,000 
cells counted from each sample. The intact cell population was identified visually and a 
manual gate was applied to eliminate the debris from the intact-cell population (Figure 
3.10A). A single-dimension histogram was plotted representing the median fluorescence 
intensity for the gated population of each sample (Figure 3.10B). Figure 3.7 represents a 
visual example of the data collected prior to analysis. Three repeats were undertaken at 
each concentration of iron cylinder used (0, 10, 25, 35, 50 and 100µM). 
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A 
 
B 
 
Figure 3.10. Representative plots for a single experiment obtained by flow cytometry for 
HL60 cells treated with Hoechst followed by iron cylinder. (A) Representative gating of 
cells treated with 25 µM iron cylinder. Black represents debris; Red represents viable 
cells. (B) Histograms produced by cells treated with different concentrations of iron 
cylinder which were used to obtain median values. For each cell type investigated, 3 
similar experiments were undertaken and the average median value was used in the 
analysis.  
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Fluorimetry results for the entire SKOV3 cell population show a concentration-dependent 
decrease in fluorescence intensity with 100 µM causing a reduction to 23 % of the control 
(p < 0.001, One-way ANOVA followed by Tukey test). Results for the gated population 
in flow cytometry also show a concentration-dependent decrease in fluorescence but to a 
lesser extent than that seen by fluorimetry (fluorescence down to 65 % when treated with 
100 µM cylinder) (Figure 3.11). These results were found to be very highly significantly 
different from the control (p < 0.001, One-way ANOVA followed by Tukey test). 
 
 
Figure 3.11. Evaluation of Hoechst fluorescence in SKOV3 cells by fluorimetry and flow 
cytometry. Cells were collected, treated for 20 minutes with Hoechst followed by 20 
minutes with cylinder at 37 
0
C prior to measuring fluorescence of the entire sample via 
fluorimetry and gated population via flow cytometry. Values are the mean of three 
separate experiments ± S.E.M. Significant difference from control, with p<0.05: *, 
<0.01: **, <0.001: ***. (One-way ANOVA followed by Tukey test).  
  ** 
*** 
  ** 
*** 
*** 
*** 
*** 
*** 
*** 
*** 
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Fluorimetry results for the entire MDAMB-231 cell population show a concentration-
dependent decrease in fluorescence intensity with 100 µM causing a reduction to 16 % of 
the control. Flow cytometry data representing the gated population also showed a 
decrease in fluorescence with increasing cylinder concentration but again to a lesser 
extent than that seen by fluorimetry (fluorescence down to 47 % when treated with 100 
µM cylinder) (Figure 3.12). These results showed that there was a very highly significant 
difference between the control and all the concentrations tested (p < 0.001, One-way 
ANOVA followed by Tukey test).  
 
 
Figure 3.12. Evaluation of Hoechst fluorescence in MDAMB-231 cells by fluorimetry 
and flow cytometry. Cells were collected, treated for 20 minutes with Hoechst followed 
by 20 minutes with cylinder at 37 
0
C prior to measuring fluorescence of the entire sample 
via fluorimetry and gated population via flow cytometry. Values are the mean of three 
separate experiments ± S.E.M. Significant difference from control, with p<0.05: *, 
<0.01: **, <0.001: ***. (One-way ANOVA followed by Tukey test).  
 *** 
*** 
 *** 
 *** 
 *** 
 *** 
 *** 
 *** 
 *** 
 *** 
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Fluorimetry results for the entire HL60 cell population show a concentration-dependent 
decrease in fluorescence intensity with 100 µM causing a reduction to less than 5 % of 
the control. Flow cytometry data representing the gated population also showed a 
decrease in fluorescence with increasing cylinder concentration but to a lesser extent than 
that seen by fluorimetry (fluorescence down to 58 % when treated with 100 µM cylinder) 
(Figure 3.13).  These results showed very highly statistically significant differences (p < 
0.001, One-way ANOVA followed by Tukey test). 
 
 
Figure 3.13. Evaluation of Hoechst fluorescence in HL60 cells by fluorimetry and flow 
cytometry. Cells were treated for 20 minutes with Hoechst followed by 20 minutes with 
cylinder at 37 
0
C prior to measuring fluorescence of the entire sample via fluorimetry 
and gated population via flow cytometry. Values are the mean of three separate 
experiments ± S.E.M. Significant difference from control, with p<0.05: *, <0.01: **, 
<0.001: *** (One-way ANOVA followed by Tukey test).  
 ** 
*** *** 
*** 
*** 
*** 
*** 
*** 
*** 
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SKOV3, MDAMB-231 and HL60 cells were collected, incubated with Hoechst and then 
treated with cylinder. Fluorimetry and flow cytometry were used to measure the 
fluorescence of samples following treatment with different cylinder concentrations. 
Fluorimetry allows a measurement of the fluorescence of the entire population in each 
sample. Flow cytometry allows a more detailed analysis of the fluorescence of just live 
cells present in each sample (selected by gating out the debris). Fluorimetry and flow 
cytometry data obtained for each cell type are shown in Figures 3.11, 3.12 and 3.13.       
 
Fluorimetry results obtained for all three cell types revealed a decrease in Hoechst 
fluorescence caused by increasing concentrations of cylinder. This provided support for 
the epifluorescence data showing that the quenching was not restricted to a few 
individual cells but was occurring for the entire population. Treatment with 100 µM 
cylinder reduced fluorescence by 77 % in SKOV3, 84 % in MDAMB-231 and 95 % in 
HL60 cells. The results showed very highly statistically significant differences from the 
control (p < 0.001). The difference in fluorescence quenching seen between the cancer 
cell types may be due to HL60 cells having increased sensitivity to the cylinder leading to 
a faster rate of uptake. The results are supported by previous research showing that 
mitochondrial function is most greatly affected by iron cylinder treatment in this cell type 
when compared with other cell types.
10 
Furthermore, the data is consistent with previous 
investigations that found Hoechst 33258 fluorescence decreased with increasing 
concentrations of cylinder in HL60 cells.
10
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Flow cytometry data also revealed a concentration-dependent decrease in fluorescence 
intensity caused by increasing cylinder concentrations. Treatment with 100 µM cylinder 
reduced the fluorescence down to 65 % in SKOV3, 47 % in MDAMB-231 and 58 % in 
HL60 cells (Figures 3.11, 3.12 and 3.13). The concentrations tested showed very highly 
statistically significant differences from the controls (p < 0.001). Despite not seeing a 
similar extent of fluorescence reduction by fluorimetry and flow cytometry, the 
concentration-dependent decrease caused by the cylinder is consistent with both methods. 
Whereas the fluorimeter gathers fluorescence data from the entire sample including dead 
cells, aggregates and artefacts, the flow cytometer produces data for a selected (live) cell 
population in each sample. This may explain the differences seen between the two 
methods used. Future work to confirm this can use fluorescence activated cell sorting to 
physically separate the gated population and then measure the fluorescence via 
fluorimetry in those sorted populations. Again, SKOV3 cells were found to show the 
most resistance to the effect of the cylinder. Data obtained from the flow cytometer 
complements the fluorimetry and epifluorescence results. We have been able to show that 
it is possible to image a non-fluorescent compound such as the iron cylinder indirectly by 
exploiting its close proximity binding to another fluorescent molecule.  
 
3.3 Conclusions and Future Work 
The data revealed that iron cylinder quenched nuclear Hoechst fluorescence possibly via 
displacement from the minor groove in a concentration-dependent manner for all the 
tumour cell types studied. Epifluorescence microscopy allowed the changes occurring in 
the fluorescence over the 20 minute treatment period to be visualized. Quenching 
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occurring at a population level through use of fluorimetry and specifically in the live cells 
in each population by using flow cytometry was then confirmed. The three methods used 
produced results that complement each other. Of the cell types investigated, SKOV3 cells 
appeared to be the most resistant to the effect of the cylinder possibly due to over 
expression of multi-drug transporters leading to efflux of cylinder from the cells. This 
data provides novel possibilities supporting the imaging of non-fluorescent compounds 
indirectly through the use of fluorescent stains. To further support the results, circular 
dichroism (CD) has been used to show iron cylinder displacement of fluorescent probes 
from DNA.
14
 A fluorescent version of the iron cylinder will function as a much better 
imaging tool and work towards this will take place in the future.       
 
It is noteworthy that there is a superfamily of proteins known as ATP-Binding Cassette 
proteins and the over expression of ABC transporters such as MRP1 and P-glycoprotein 
has been identified in many cancer cells. They are believed to be responsible for the 
export of chemotherapeutics across the plasma membrane and therefore a reduced effect 
of anticancer treatment. The increased resistance displayed by SKOV3 cells to iron 
cylinder may be due to the over expression of certain multidrug resistance proteins.
15
 
Future work may involve using inhibitors to confirm over expression of certain drug 
transporters in the plasma membranes of SKOV3 cells or real-time polymerase chain 
reaction (PCR) to look at expression levels. The Hoechst quenching raises the question of 
whether other intrinsic fluorescent markers in cells might also be quenched to aid in 
visualizing entry of the cylinder and this is explored in the next chapters.   
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CHAPTER 4 
 
 
Investigating Luciferase Quenching as a Novel Method of 
Imaging the Non-Fluorescent Iron Cylinder  
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4.1 Introduction 
The work in this chapter builds on serendipitous observations made while employing the 
ToxiLight assay which was being used as an alternative to the MTT assay used to assess 
cell viability in Chapter 3. Although, The MTT assay is one of the most popular assays 
used to assess cell viability or detect cytotoxicity and it is generally accepted that the 
quantity of MTT formazan produced is directly related to cell viability,
1 
this is 
complicated because it can also be considered an indicator of cell number and its 
applicability as a viability endpoint has been debated.
2
 Recently, a number of researchers 
have also questioned the two commonly held assumptions of the MTT assay. The first is 
that the reduction of the MTT dye takes place in the mitochondria and the second is that 
this particular assay is a sufficient assessor of mitochondrial function and therefore a 
suitable evaluator of this organelle’s activity.2   
 
It is important to assess the cytotoxicity of a compound using a range of different assays 
designed to measure this and confirm viability using different endpoints. The ToxiLight 
assay is a highly sensitive non-destructive cytotoxicity assay which quantifies the leakage 
of adenylate kinase from cells whose membranes have been damaged. The reaction 
involved in this assay proceeds in two steps. In the first step, ADP is supplied in excess 
as the substrate and converted to ATP by the enzyme adenylate kinase (if present). In the 
second step, the bioluminescent reaction occurs where the enzyme luciferase uses the 
substrates ATP and luciferin to catalyze the production of light. The light given off is 
quantified using a luminometer and is directly related to the level of ATP and thus the 
amount of adenylate kinase present in the sample being analyzed.  
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Bioluminescent assays are extensively used in medical research with applications in 
many areas including cell viability testing and in vivo/ in vitro imaging. Fireflies 
(Photinus pyralis) are the best-studied bioluminescent organisms and the firefly 
luciferase enzyme is a popular tool used in imaging assays. The substrate for the enzyme 
is luciferin and for the reaction to occur, oxygen, ATP and a metallic cation are required 
(Figure 4.1).
3
 D-luciferyl-adenylate is the enzyme bound intermediate produced in the 
reaction which undergoes oxidation, decarboxylation and is converted to a singlet excited 
state of oxyluciferin. As the oxyluciferin decays from its excited state to the ground state, 
emission of a photon at 562 nm occurs which follows a model of flash kinetics with the 
emission intensity rapidly decaying within just a few seconds.
4
 
 
The structure of the luciferase protein has been well studied and is comprised of two 
folded domains close together (Figure 4.2). The small C-terminal domain is joined by a 
linker peptide to the larger N-terminal domain. The surface of both domains is believed 
to form the active site implying that they get closer together as the reaction proceeds 
holding the substrate between them which would require a change in the enzyme’s 
conformation.
3
  
 
Figure 4.1. The structure of luciferin and the chemical reaction carried out by firefly 
luciferase to produce a peak light emission wavelength.
 
Taken from ref 4. 
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Figure 4.2. Space-filling model of firefly luciferase showing the small C-terminal domain 
linked by the flexible linker peptide (L) to the large N-terminal domain. Taken from ref 3. 
 
Many systems based on luciferase have been developed because the enzyme can be 
introduced into cells genetically. In vivo imaging has recently been developed as a 
method to non-invasively monitor events occurring at a molecular level in model 
organisms and cells in vitro.
3
 The labeling of proteins with luciferases which are then 
imaged following addition of substrate can be used to localize processes occurring in 
cells and organisms. A compound that interferes with this bioluminescent reaction 
catalyzed by luciferase or quenches the product could ultimately lead to development of a 
method to indirectly confirm the localization of the compound in vivo and this is further 
investigated with regards to iron cylinder in Chapter 4.      
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4.2 Results and Discussion 
4.2.1 Cytotoxicity Assessed by ToxiLight Assay  
The Lonza ToxiLight assay was used as an alternative approach to complement the MTT 
assay and assess the damage caused to cells by a cylinder. Due to financial constraints, 
one cell line was selected (MDAMB-231) for use in the ToxiLight Assay. Leakage of 
adenylate kinase from cells into the surrounding media was measured in MDAMB-231 
cells at five different concentrations of iron cylinder. The ToxiLight assay was carried out 
following a 20 minute treatment period with iron cylinder at 37 
0
C. The percentages of 
luminescence shown in the results were calculated using the average luminescence of 
three readings. Using this assay, integrity of the plasma membrane would be identified 
through no change in luminescence output with increasing concentrations of cylinder. 
Alternatively, an increase in luminescence with increasing cylinder concentration would 
indicate damage occurring to the plasma membrane as a result of treatment. However, the 
results we obtained for this assay were unexpected and revealed a clear concentration-
dependent decrease in luminescence caused by iron cylinder (Figure 4.3).    
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Figure 4.3. ToxiLight assay carried out for MDAMB-231 cells following treatment with 
iron cylinder. Cells were treated with iron cylinder for 20 minutes at 37 
0
C prior to 
measuring luminescence. Values are the mean of three separate experiments ± S.E.M. 
Significant difference from control, with p<0.05: *, <0.01: **, <0.001: ***. (One-way 
ANOVA followed by Tukey test). 
 
Luminescence was reduced to 43 % when cells were treated with 100 µM cylinder and 
statistically this result was very highly significantly different from the control (p < 0.001, 
One-way ANOVA followed by Tukey test). These results suggested that the cylinder was 
inhibiting the ToxiLight assay. A working hypothesis was that it may be acting by 
inhibiting the actions of one of the enzymes present in the detection reagent. Further 
investigations were needed to determine the mechanism by which the drug was exhibiting 
its effect on this assay.        
 
 
*** ** 
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4.2.2 Investigations into Cylinder Interference with ToxiLight Assay Kit 
Cell lysate obtained from MDAMB-231 cells containing adenylate kinase was used to 
confirm the interference of iron cylinder with the ToxiLight assay kit. Cells were treated 
with lysis buffer to damage their membranes and release large amounts of adenylate 
kinase into the surrounding media. This was then incubated with iron cylinder (0-150 
µM) prior to carrying out the ToxiLight assay. The percentages of luminescence shown 
in the results were calculated using the average luminescence of three readings (Figure 
4.4). Any changes observed in the luminescence would be occurring as a result of the 
direct effect of the cylinder’s activity.  
 
 
Figure 4.4. Evaluation of interference by iron cylinder on ToxiLight assay using 
MDAMB-231 cell lysate.  Cell lysate was treated with iron cylinder prior to carrying out 
the ToxiLight assay and measuring luminescence. Values are the mean of three separate 
experiments ± S.E.M. Significant difference from control, with p<0.05: *, <0.01: **, 
<0.001: ***. (One-way ANOVA followed by Tukey test).  
*** 
*** 
*** 
*** 
  
110 
 
The results show a concentration-dependent decrease in luminescence with increasing 
concentrations of iron cylinder. The highest concentration of cylinder reduced 
luminescence by 90 % compared to the control (Figure 4.4). A very highly significant 
difference was identified between the control and all the concentrations of cylinder tested 
(p < 0.001, One-way ANOVA followed by Tukey test). These results confirm that the 
cylinder was responsible for the decrease in luminescence observed for the ToxiLight 
assay. The next step was to further investigate the mechanism by which the cylinder was 
reducing the luminescence.  
 
The cylinder’s ability to inhibit the enzyme luciferase as its possible mechanism of action 
was then investigated. The ToxiLight assay uses the two enzymes, adenylate kinase and 
luciferase in two separate steps. In the first step, ADP is phosphorylated to ATP 
(substrate for luciferase) by adenylate kinase. This step was bypassed by supplying an 
excess of ATP (1 mM in final volume of 100 µl) in a cell free system prior to testing the 
five concentrations of iron cylinder. Cylinder was then added and the assay carried out as 
before. The ToxiLight assay was carried out following cylinder treatment. The 
percentages of luminescence shown in the results were calculated using the average 
luminescence of three readings (Figure 4.5). 
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Figure 4.5. Evaluation of luciferase inhibition by iron cylinder in a cell-free system. ATP 
was supplied in excess prior to cylinder addition. The ToxiLight assay was carried out 
and luminescence measurements obtained. Values are the mean of three separate 
experiments ± S.E.M. Significant difference from control, with p<0.05: *, <0.01: **, 
<0.001: ***. (One-way ANOVA followed by Tukey test). 
 
The results show a concentration-dependent decrease with the luminescence reduced to 
less than 6 % with 100 µM iron cylinder (Figure 4.5). A very highly significant 
difference was found to exist between the concentrations tested (p < 0.001, One-way 
ANOVA followed by Tukey test). This provided evidence for the inhibition of luciferase 
being a possible mechanism by which iron cylinder was interfering with the ToxiLight 
assay. Supplying the excess of ATP allowed adenylate kinase to be eliminated as the 
enzyme responsible for the effect caused by the drug on the ToxiLight assay.  
 
   *** 
*** 
*** 
*** 
*** 
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To ensure that the inhibition seen in luminescence was a result of intact cylinder, the role 
of individual components required to synthesize the cylinder was investigated. The 
synthesized ligand, its components (4,4‟-methylenedianiline and pyridine-2-
carboxaldehyde) and iron(II) chloride tetrahydrate were tested in the same way. ATP was 
supplied in excess prior to addition of compound. The ToxiLight assay was carried out 
and the luminescence measured for each concentration tested. The percentages of 
luminescence shown in the results were calculated using the average luminescence of 
three readings (Figure 4.6). 
 
 
Figure 4.6. Investigating the role of the ligand and cylinder components in luciferase 
inhibition. ATP was supplied in excess prior to compound addition. The ToxiLight assay 
was carried out and luminescence measurements obtained. Values are the mean of three 
separate experiments ± S.E.M. Significant difference from control, with p<0.05: *, 
<0.01: **, <0.001: ***. (One-way ANOVA followed by Tukey test). 
*** 
*** 
*** *** *** *** 
** 
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The results show that iron(II) chloride tetrahydrate and pyridine-2-carboxaldehyde did 
not reduce the luminescence significantly which was over 100 % when 100 µM of each 
compound was tested (Figure 4.6). There was no significant difference between any of 
the concentrations tested of these two compounds (p > 0.05, One-way ANOVA). The 
results suggest that these components are not dissociating from the cylinder in solution 
and provide support for the stability of the cylinder. The luminescence was reduced by 24 
% of the control in a concentration-dependent manner by 100 µM 4,4‟-
methylenedianiline. However, as this reduction in luminescence was not to the same 
extent as that seen for the intact cylinder, 4,4‟-methylenedianiline alone is unlikely to be 
responsible for the inhibition. The greatest reduction in luminescence was observed with 
increasing concentrations of ligand (luminescence reduced to less than 1 % of the control 
when treated with 50 and 100 µM ligand). A very highly significant difference was found 
to exist between the concentrations tested (p < 0.001, One-way ANOVA followed by a 
Tukey test). There may be many explanations for this reduction in luminescence caused 
by the ligand alone. One possible theory is that the ligand could be dissociating in 
solution and then chelating other metal species present in the ToxiLight detection reagent 
such as Mg
2+
. To further investigate this metal chelators were used. 
 
The chelating ligands: 2,2’-bipyridine and 1,10’-phenanthroline that readily form 
complexes with metal ions were also examined for their effect on the ToxiLight assay. 
ATP was supplied in excess prior to addition of compound. Increasing concentrations of 
both were used to test their ability to chelate free metal ions present in the assay. The 
ToxiLight assay was carried out and the luminescence measured for each concentration 
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tested. The percentages of luminescence shown in the results were calculated using the 
average luminescence of three readings (Figure 4.7). 
 
 
Figure 4.7. Investigating the role of chelating ligands in luciferase inhibition. ATP was 
supplied in excess prior to compound addition. The ToxiLight assay was carried out and 
luminescence measurements obtained. Values are the mean of three separate experiments 
± S.E.M. Significant difference from control, with p<0.05: *, <0.01: **, <0.001: ***. 
(One-way ANOVA followed by Tukey test). 
 
The results show that luminescence was reduced by 17 % of the control by 100 µM of 
2,2’-bipyridine. None of the concentrations tested were found to be significantly different 
from each other (p > 0.05, One-way ANOVA). Luminescence was reduced to a greater 
extent by 1,10’-phenanthroline (42 % with 100 µM compound). A very highly 
statistically significant difference was found between the control and top dose of this 
compound (p < 0.001, One-way ANOVA followed by Tukey test) However, the 
*** 
** 
*** 
*** 
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luminescence was not reduced to the same extent by the chelating ligands as that seen for 
the iron cylinder’s ligand (Figure 4.7). 
 
This suggests that the decreased luminescence seen to be caused by the iron cylinder’s 
ligand was unlikely to be due to dissociation from the metal complex and more likely to 
be the effect of the complete cylinder. This is in agreement with stability data of the 
cylinder in aqueous solution. Much research has investigated the interaction between iron 
cylinder and DNA with molecular dynamic calculations and NMR spectroscopy 
supporting its ability to bind strongly to DNA and induce conformational changes (see 
section 1.8). This provides further evidence for the cylinder remaining intact and any 
responses observed being due to the actions of the complete compound. 
 
4.2.3 Monitoring Luminescence Production Over Time in MDAMB-231 Cells Stably 
Expressing Luciferase   
First the emission of luminescence from luciferase- expressing MDAMB-231 cells was 
quantified following addition of the substrates, ATP and luciferin (1 mM for each in final 
volume of 100 µl). As expected, the non-expressing MDAMB-231 cell line emitted very 
little light (76 luminescence units) when exposed to the substrates. This cell line provided 
the negative control for the experiment. A very high luminescence output of 16406 
luminescence units was produced in the luciferase-expressing cancer cell line upon 
substrate addition (Figure 4.8). This experiment allowed us to determine the 
concentrations of luciferin (1 mM) and ATP (1 mM) required for the luciferase-
expressing MDAMB-231 cells to catalyze the bioluminescent reaction and produce light. 
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Figure 4.8. Confirming luminescence production in luciferase-expressing MDAMB-231 
cell line. ATP and luciferin were supplied prior to obtaining luminescence measurements. 
Values are the mean of three separate experiments ± S.E.M. 
 
The period of time over which the strength of the luminescent signal was maintained was 
then investigated. To achieve this, cells were incubated with substrates (using 
concentrations defined previously) and the luminescence was measured at intervals over 
30 minutes. The luminescence values shown for each time point were calculated using 
the average luminescence of three recordings (Figure 4.9). The results show that 4 
minutes after exposure to substrate, the signal is reduced by 84 % when compared to that 
measured at 2 minutes in luciferase-expressing MDAMB-231 cells. Following the sudden 
decline after 4 minutes, the luminescence continues to increase very slowly with time. 
Despite this, it does not increase to the emission observed at 2 minutes (at 28 minutes, the 
signal is still only 24 % of the signal acquired at 2 minutes). This confirmed that the 
luciferase enzyme had flash kinetics with maximum sensitivity due to the high signal 
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intensity produced despite the rapid decay of the light emitted. As expected, the non-
expressing MDAMB-231 cells produced no luminescence output when exposed to 
substrate which was consistent over the time course.  
 
 
Figure 4.9. Investigating strength of luminescent signal in luciferase-expressing 
MDAMB-231 cells over time. ATP and luciferin were supplied prior to obtaining 
luminescent measurements. Values are the mean of three separate experiments ± S.E.M. 
 
An MTT assay was used to assess mitochondrial viability in luciferase-expressing and 
non-expressing MDAMB-231 cells that had been treated with concentrations of iron 
cylinder for 20 minutes followed by exposure to ATP and luciferin. The percentages of 
viable mitochondria shown in the results were calculated using the average absorbance of 
three readings (DMSO blank adjusted). The results show that over 95 % of cells 
remained viable in both cell types when treated with the top dose of iron cylinder (100 
µM). No statistical significance was observed between any of the concentrations 
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investigated (p > 0.05, Kruskal-Wallis test) (Figure 4.10). These results determined that 
treatment with cylinder together with exposure to substrates (at the concentrations pre-
determined) did not cause any significant effect on the reductive function of mitochondria 
and therefore on cell viability. Any effects on luminescence inhibition seen in these cells 
following treatment could therefore not be associated with cytotoxicity as a result of drug 
or substrates. Therefore, concentrations of 0, 10, 25, 35, 50 and 100 µM were used in all 
future assays where cells were treated for 20 minutes with drug and then substrate. 
 
 
Figure 4.10. Evaluation of cytotoxic effects of substrates and iron cylinder treatment in 
luciferase-expressing MDAMB-231 cells using the MTT assay. Cells were treated with 
iron cylinder for 20 minutes at 37 
0
C prior to ATP and luciferin addition and measuring 
MTT reduction. Values are the mean of three separate experiments ± S.E.M. No 
significant difference from control (p>0.05 in MDAMB-231, luciferase-expressing 
MDAMB-231 cells, Kruskal-Wallis test). 
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4.2.4 Investigating Iron Cylinder’s Inhibition of Luminescence in Luciferase- 
Expressing MDAMB-231 Cells   
The cylinder’s effect on luminescence production in luciferase-expressing MDAMB-231 
cell lysate was tested. Cells membranes were lysed and then treated with increasing 
concentrations of iron cylinder (0, 10, 25, 35, 50, 100 µM) for 20 minutes at 37 
0
C. ATP 
and luciferin were supplied and the luminescence recorded. Cells were lysed to ensure 
that the cylinder had direct access to the contents of the cell and therefore its effect on 
luminescence could be measured without any access barriers.  Non-expressing MDAMB-
231 cells were present as a control. A negative control was also present for each cell type 
where substrates were not provided before the luminescence recording. The luminescence 
values shown in the results were calculated using the average of three readings (Figure 
4.11). 
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Figure 4.11. Evaluation of luciferase inhibition by iron cylinder in lysed luciferase-
expressing MDAMB-231 cells. Lysed cells were treated with iron cylinder for 20 minutes 
at 37 
0
C prior to ATP and luciferin addition and luminescence recorded. Values are the 
mean of three separate experiments ± S.E.M. Significant difference from control, with 
p<0.05: *, <0.01: **, <0.001: ***. (One-way ANOVA followed by Tukey test). 
 
The results showed that the cylinder caused a concentration-dependent decrease in 
luminescence which only occurred in the lysed luciferase-expressing MDAMB-231 cells 
that were supplied with substrate (luminescence reduced by 76 % of the control when 
treated with 100 µM drug) (Figure 4.11). Each concentration of cylinder tested was found 
to be very highly statistically significantly different from the control (p < 0.001, One-way 
ANOVA followed by Tukey test). These results provide support for the hypothesis that 
this cylinder inhibits the bioluminescent reaction possibly via inhibition of the luciferase 
enzyme. 
 
*** 
*** 
*** 
*** 
*** 
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Next, the cylinder’s ability to inhibit this reaction in luciferase-expressing MDAMB-231 
cells with intact membranes was tested. Cells were trypsinized before being treated with 
increasing concentrations of iron cylinder (0, 10, 25, 35, 50, 100 µM) for 20 minutes at 
37 
0
C. ATP and luciferin were supplied and the luminescence recorded. Non-expressing 
MDAMB-231 cells were present as a control. A negative control was also present for 
each cell type where substrates were not provided before luminescence recording. The 
luminescence values shown in the results were calculated using the average of three 
readings (Figure 4.12). 
 
 
Figure 4.12. Evaluation of luciferase inhibition by iron cylinder in trypsinized luciferase-
expressing MDAMB-231 cells. Trypsinized cells were treated with iron cylinder for 20 
minutes at 37 
0
C prior to ATP and luciferin addition and luminescence recorded. Values 
are the mean of three separate experiments ± S.E.M. Significant difference from control, 
with p<0.05: *, <0.01: **, <0.001: ***. (One-way ANOVA followed by Tukey test). 
 
*** 
*** 
*** *** *** 
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The results revealed a concentration-dependent decrease in luminescence caused by 
increasing concentrations of iron cylinder which only occurred in luciferase-expressing 
MDAMB-231 cells following treatment with substrates. Luminescence was reduced by 
88 % of the control when treated with the top concentration of 100 µM of cylinder. For 
each of the concentrations tested, a very high statistical significance was found in terms 
of difference from the control (p < 0.001, One-way ANOVA followed by Tukey test) 
(Figure 4.12).  
 
The results indicate that iron cylinder is able to cross the cell membrane and inhibit the 
bioluminescent reaction in cells which have detached from a surface but still have their 
membranes intact. These results support data obtained for lysed cells and provide further 
support for the cylinder’s inhibition of luminescence in a concentration-dependent 
manner via luciferase inhibition taking place in the cell. 
 
Finally we investigated this inhibition in adherent cells. Cultured cells attached to a 
surface were treated increasing concentrations of iron cylinder (0, 10, 25, 35, 50, 100 
µM) for 20 minutes at 37 
0
C. ATP and luciferin were supplied and the luminescence 
recorded. MDAMB-231 cells were present as a control. A negative control was also 
present for each cell type where substrates were not provided before recording 
luminescence. The luminescence values shown in the results were calculated using the 
average of three readings with concentrations of drug (Figure 4.13).  
  
123 
 
 
Figure 4.13. Evaluation of luciferase inhibition by iron cylinder in adherent luciferase-
expressing MDAMB-231 cells. Adherent cells were treated with iron cylinder for 20 
minutes at 37 
0
C prior to ATP and luciferin addition and luminescence recorded. Values 
are the mean of three separate experiments ± S.E.M. Significant difference from control, 
with p<0.05: *, <0.01: **, <0.001: ***. (One-way ANOVA followed by Tukey test). 
 
The results support those obtained for lysed and trypsinized cells with a concentration-
dependent decrease in luminescence caused by iron cylinder which only occurred in 
luciferase-expressing MDAMB-231 cells following exposure to substrates. 
Luminescence was reduced by 90 % of the control when treated with the top 
concentration of 100 µM of cylinder. For each of the concentrations tested, a very high 
statistical significance was found in terms of difference from the control (p < 0.001, One-
way ANOVA followed by Tukey test) (Figure 4.13). The results indicate that iron 
cylinder is able to efficiently cross the cell membrane of cancer cells growing in culture 
and inhibit the bioluminescent reaction occurring in these cells. 
*** 
*** 
*** *** 
*** 
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Recent research carried out on a novel chemotherapeutic naphthoquinone drug, TU100 
(Figure 4.14) has revealed that this too inhibits the bioluminescent enzyme, luciferase. 
This drug also irreversibly inhibits topoisomerase enzymes which are responsible for 
regulating the winding and unwinding of DNA. Its effects seen on the luciferase enzyme 
were found to proceed through different mechanisms which were reversible. The effect of 
naphthoquinone was investigated on a range of concentrations for the luciferase 
substrates, ATP and luciferin. The results revealed that the drug binds competitively with 
regards to luciferin and uncompetitively with regards to ATP. The results imply that the 
drug specifically binds the luciferase-ATP complex, preventing it from interacting with 
the luciferin and therefore inhibiting the bioluminescent reaction from occurring.
5
 Light 
emission from luciferase-expressing kidney epithelial cells was reduced to 60 % when 
treated with 10 µM TU100. In comparison, treatment of luciferase-expressing breast 
cancer cells with 10 µM iron cylinder caused a much greater reduction to 10 % of the 
control. 
O
O
N CH3
 
Figure 4.14. The structure of the novel naphthoquinone drug, TU100. 
 
The iron cylinder might act via this mechanism also which makes it an important novel 
agent for the investigation and regulation of bioluminescent enzymes. Another possibility 
is that the iron cylinder directly interferes with the enzyme luciferase by irreversibly 
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binding to the active sites in the C/N-terminal or the peptide linker region, thereby 
preventing the enzyme from changing conformation and allowing substrates to bind at the 
active site which would prevent the reaction from proceeding (Figure 4.2).   
 
4.2.5 Investigating Quenching of Luminescence by Iron Cylinder in Adherent 
Luciferase- Expressing MDAMB-231 Cells with Time  
The iron cylinder’s inhibition of the bioluminescent reaction over time was investigated 
with decay of the luminescent signal produced by luciferase expressing MDAMB-231 
cells in the presence of substrate. Cells were treated with increasing concentrations of 
iron cylinder (0, 10, 25, 35, 50, 100 µM) for 20 minutes at 37 
0
C. ATP and luciferin were 
supplied and the luminescence recorded at 3 minute intervals over a 30 minute period. 
The results show a reduction in the luminescent signal of untreated cells by 90 % after 4 
minutes of exposure to substrates when compared to the signal at 2 minutes after 
exposure (Figure 4.15).  
 
These results support previous data showing a reduction in luminescence to 84 % at 4 
minutes when compared to the signal produced at 2 minutes (Figure 4.9). The 
luminescence produced at 2 minutes after substrate exposure showed that 100 µM iron 
cylinder reduced the signal by 99 % of the control. The signal measured at 28 minutes 
showed the same concentration of cylinder reduced the luminescence by 96 % of the 
control (Figure 4.15). These results indicate that despite the flash kinetic nature of the 
luciferase with the signal decaying rapidly, the proportion by which the cylinder inhibits 
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this bioluminescent reaction is similar at 2 minutes and 28 minutes (100 µM drug 
reduced signal to 1 % of control at 2 minutes and 4 % at 28 minutes).  
 
Therefore, despite the large difference in luminescence output at 2 minutes (24406 
luminescence units) compared to 4 minutes (3937 luminescence units), the cylinder’s 
ability to inhibit the bioluminescent reaction is proportionally consistent at each time 
point (Figure 4.15). This implies that data obtained at a later time point is equally valid as 
that obtained at an earlier one as long as the time point chosen is kept consistent across 
experiments.    
 
 
Figure 4.15. Investigating intensity of luciferase inhibition by iron cylinder in adherent 
luciferase-expressing MDAMB-231 cells over time. Cells were treated with iron cylinder 
prior to addition of substrates and luminescence measured at 3 minute intervals over a 
30 minute period. Values are the mean of three separate experiments ± S.E.M. 
 
  
127 
 
Investigations into the cylinder’s ability to inhibit a bioluminescent reaction provided 
another indirect mechanism by which this cylinder could be imaged. Its ability to block 
the mechanism by which a luminescent enzyme functions has the potential to be 
exploited for a number of studies. The quenching of light could be used to study 
biological processes occurring in real time as well as identifying the localization of this 
cylinder in cells and model organisms. Recently, bioluminescent imaging has been used 
to quantify and assess the efficacy of drugs in cancer research.
6
 The light emitted when 
the excited oxy-luciferin relaxes back to its ground state can pass through mammalian 
tissues and can be used to investigate luciferase-expressing cancer cells non-invasively. 
However, many challenges remain in the development of animal models which can be 
used to sensitively study tumor development. Problems on the molecular level include 
development of effective methods to image using reporter systems that show cell 
processes occurring over time. When luciferase is used as a reporter, luciferin has to be 
supplied externally which is often not a practical approach in vivo for larger models such 
as rodents.  
 
In addition, as the luciferin is rapidly used up, the bioluminescence signal can become 
increasingly unstable. Photons are both scattered and absorbed in the complex medium 
that makes up mammalian tissue. This is caused by changes which occur in the refractive 
index at organelles and membranes within the cell. These can limit the ability of studies 
to look at deep tissues due to scattering and a diminished signal.
6
 Furthermore, other 
factors including the iron cylinder’s ligand may interfere with the luciferase so this may 
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not be an ideal reaction. Therefore, research moved to investigate green fluorescent 
protein (GFP) in chapter 5.       
 
4.3 Conclusions and Future Work 
Through the use of luciferase-expressing breast cancer cells it has been shown that the 
cylinder directly affects luciferase-dependent light production in cells and does so in a 
concentration-dependent manner. The cylinder may be having its effect by physically 
interacting with the ATP-luciferase complex and preventing it from having access to the 
luciferin substrate. As a result, the production of oxyluciferin and light would be 
inhibited and the bioluminescent reaction blocked.  
 
Kinetic analysis of iron cylinder’s inhibition would provide further insight into which 
step of the biolumisnescent reaction is being affected, as well as giving information about 
the mechanism of inhibition. These experiments would involve determining Km values 
for luciferin and ATP (the substrate concentration at which half the enzyme's active sites 
are occupied by substrate), holding one substrate at its Km whilst titrating the other in. 
Analysis of the orientation of the straight line series generated from reciprocal plots 
would allow confirmation of competitive/uncompetitive binding of cylinder with respect 
to ATP and luciferin.
5
   
 
The application where luciferase acts as a reporter gene has been well-established. This 
produces a signal that can be quantified under certain conditions, providing information 
about cell processes including receptor activity, gene expression patterns and protein-
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protein interactions. An expression vector such as a plasmid carrying the luc gene is 
introduced into an organism and once inside a cell, the working luciferase protein is 
produced via translation of the luc gene. The ATP and luciferin substrates are supplied 
which leads to production of light and can be detected via a luminometer. This method 
has been employed in drug-screening and to identify certain sequences or parts of the 
genome. Bioimaging has been established since then which allows the emission of light 
to be followed in an animal (Figure 4.16) by placing the animal under a photon-detecting 
CCD (charge-coupled device).
3
  
 
 
Figure 4.16. Reporter gene technology related to luciferase. A regulatory sequence (A) is 
present on the expression vector which is introduced into the cell. (A) controls expression 
of the luc gene (B) leading to luciferase protein production. Light emission can be 
quantified in cells or in an organism when ATP and luciferin substrates are administered 
prior to acquiring data.
 
Taken from ref 3. 
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The inhibition of luciferase by iron cylinder is a very significant finding and could 
provide further insight into the distribution of this compound in vivo. For example, a 
transgenic mouse expressing luciferase cells or implanted with luciferase-expressing 
cancer cells could be used as a model to study distribution of cylinder in vivo and uptake 
into cancer cells. Following administration of substrates required for the luminescent 
reaction to occur, iron cylinder treatment would take place possibly through intravenous 
injection. Light emitted from the cancer cells would then be monitored over time which 
would provide information about the activity and location of the iron cylinder in the 
mouse. Tumour development could be quantified by using the inhibition of luciferase by 
cylinder and this could be compared in relation to untreated animals.     
 
Drug inhibition of bioluminescent reactions has recently been investigated. Animals are 
usually anaesthetized prior to imaging using compounds such as lidocaine and halothane, 
both of which are known to directly inhibit the enzyme luciferase by binding and altering 
its catalytic speed.
7
 A recent study compared the inhibitory effect of different types of 
anesthetics commonly used to sedate mice and rats. In vitro findings showed that all the 
volatile anesthetics tested caused a clear inhibitory effect on the activity of the luciferase 
enzyme with Avertin having the strongest inhibition. In vivo effects were largely due to 
changes in blood movement and to a lesser extent due to direct drug-enzyme interactions. 
The researchers concluded that it was best to use unanaesthetized animals for 
bioluminescent imaging but if necessary, phenobarbital was the best suited anaesthetic to 
use.
7
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In this Chapter, another novel method has been identified to indirectly image the non-
fluorescent drug by using its inhibition of the luminescent enzyme, luciferase. However, 
it may be subject to effects from other molecular species including the iron cylinder’s 
ligand and this needs to be considered when analyzing its effects. 
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CHAPTER 5 
 
 
Investigating GFP Quenching as a Novel Method of Imaging 
the Non-Fluorescent Iron Cylinder  
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5.1 Introduction 
The work in this chapter builds on the results from bioluminescent observations in 
Chapter 4 which demonstrates proof of principal that the iron cylinder can be imaged 
with no fluorescent protein probes. Due to various considerations including factors that 
may influence the enzyme luciferase, research moved to investigate the green fluorescent 
protein (GFP) in this chapter. 
 
Being able to image a molecule having its effect at a cellular level is very important in 
order to identify and study cellular proteins including those involved in cancer 
development. Bioluminescence imaging can be used to visualize cancer cells in vivo by 
expressing the luciferase gene in cancer cells enabling light emission from cells to be 
studied. However, there are several limitations to this approach. The luciferase enzyme, 
once inside mammalian cells needs to be supplied externally with the substrate luciferin. 
This is required each time imaging is being carried out which is not a practical method 
for whole organism studies. Using this method produces poor resolution of image and 
diminished signal. Therefore, long integration times are required to detect enough signal 
to construct an image from the animal. In addition, it is not known whether the luciferase 
genes have a stable expression in tumors over time as the luminescence emitted depends 
on the metabolic activity of the cells which have been transfected with luciferase.
1,2
 
Fluorescent imaging offers a number of advantages when compared to bioluminescent 
imaging.  
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An intense, highly specific signal with good resolution and physiological conditions is 
essential to image tumor development externally. Green fluorescent protein (GFP) was 
chosen as it meets these requirements and has good potential as a cell marker.
1
 GFP was 
cloned from Aequorea jellyfish and discovered alongside the well-known chemi-
luminescent protein, aequorin.
3
 GFP absorbs blue light, re-emitting it as green 
fluorescence.
4
 It is spontaneously fluorescent requiring no other proteins, co-factors or 
substrates.
1
 In addition to Aequorea, GFP has also been found in a range of other 
symbiotic and non-symbiotic cnidarians. Here, it is not in conjunction with a 
bioluminescent system and its function is unknown.
4 
During spontaneous cyclization and 
oxidation of the amino acid chain during protein folding, the GFP chromophore is 
formed. The chromophore has to be kept well protected deep within the barrel-shaped 
protein to produce the fluorescence (Figure 5.1). The cellular pH and other factors of the 
microscopic environment affect the intensity of GFP fluorescence and have been taken 
advantage of with the availability of pH and redox sensitive GFPs which can be used as 
probes.
4
    
 
Figure 5.1. 3D structure of GFP, showing 11 β-strands that form a hollow cylinder 
through which is threaded an α-helix containing the chromophore. Taken from ref 3. 
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GFP has been used to visualize numerous active processes taking place in cells including 
interactions of proteins and chromosome dynamics. Its use as a reporter gene was one of 
its first successful applications where the GFP gene is controlled by a promoter of interest 
and the fluorescence emitted can be used to indicate the level of gene expression in cells 
and tissues.
5 
Furthermore, fusion of a cloned gene of interest with GFP has led to the 
development of chimeric proteins which are then expressed in cells and tissues. The 
design of the hisone-GFP fusion protein allowed small fragments of extra-chromosomal 
DNA known as double minute chromosomes to be visualized. Double-minute 
chromosomes have a vital role in the genetics of cancer cells as they are commonly 
linked with the overexpression of oncogene proteins.
6
 
 
GFP has been stably expressed in certain cancer cell lines in vitro and these cells have 
successfully been transplanted into animals including rodents where they have been 
imaged in specific organs. Metastatic disease models using GFP have been defined for a 
range of cancers including breast, ovarian and prostate tumors.
1
 Transfection of GFP into 
cancer cells provides a useful tool to image tumor growth and development in vivo.
1 
In 
this chapter, the effect of the cylinder on GFP fluorescence is investigated and a method 
to directly visualize the location and mechanism of the cylinder in vitro is developed.      
 
5.2 Results and Discussion 
5.2.1 Investigating Quenching of Purified GFP by Iron Cylinder 
The fluorescence of purified GFP was measured in the presence of different 
concentrations of iron cylinder (0, 10, 25, 35, 50 and 100 µM in final volume of 100 µl). 
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GFP (0.5 µM in final volume of 100 µl) was diluted in distilled water prior to treatment 
with cylinder (20 minutes at 37 
0
C for each concentration tested). A fluorimeter was used 
to record the fluorescence of each sample (λexc = 485 nm, λem = 530 nm).  Three repeats 
were collected at each concentration of iron cylinder tested and the data was blank 
adjusted to remove background fluorescence of cylinder alone for each of the 
concentrations investigated (Figure 5.2).  
 
 
Figure 5.2. Evaluation of fluorescence quenching of purified GFP by iron cylinder. GFP 
was treated for 20 minutes with iron cylinder at 37 
0
C prior to measuring fluorescence 
via fluorimetry. Values are the mean of three separate experiments ± S.E.M. Significant 
difference from control, with p<0.05: *, <0.01: **, <0.001: ***. (One-way ANOVA 
followed by Tukey test).  
 
 
*** 
*** *** *** 
*** 
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Using this purified GFP in vitro allows direct investigation of the interaction of the 
cylinder with GFP, in the absence of endogenous mammalian proteins. Fluorimetry 
results show that exposure to 10 µM cylinder reduced fluorescence of GFP by 82 % of 
the control and this further decreased to 94 % when the protein was exposed to the top 
concentration of 100 µM cylinder. The results were found to be very highly significantly 
different from the control (p < 0.001, One-way ANOVA followed by Tukey test). These 
results indicate that the cylinder interacts with the GFP in solution and quenches its 
fluorescence. As the GFP chromophore is well protected in the protein’s structure and 
this is required for it to fluoresce, these results suggest that the cylinder is able to access 
the core of this protein and inhibit its function, resulting in the decreased fluorescence 
observed.  
 
5.2.2 Investigating GFP Quenching by Iron Cylinder in MDAMB-231 Cells Stably 
Expressing GFP 
Next it was investigated whether the cylinder would be able to access GFP when it was 
present in a cellular environment. The fluorescence of adherent GFP-expressing 
MDAMB-231 cells was measured at different concentrations of iron cylinder (0, 10, 25, 
35, 50 and 100 µM). Cells were treated with cylinder for 20 minutes at 37 
0
C for each 
concentration tested. A fluorimeter was used to record the fluorescence of each sample 
(λexc = 485 nm, λem = 530 nm) and three repeats were present at each concentration of 
iron cylinder tested. The data was blank adjusted using fluorescence values obtained from 
non-expressing MDAMB-231 cells treated with concentrations of cylinder (Figure 5.3).  
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Figure 5.3. Evaluation of fluorescence quenching in GFP-expressing MDAMB-231 cells 
by iron cylinder. Cells were treated for 20 minutes with iron cylinder at 37 
0
C prior to 
measuring fluorescence via fluorimetry. Values are the mean of three separate 
experiments ± S.E.M. No significant difference from control (p>0.05, One-way ANOVA). 
 
Results show a concentration-dependent decrease in GFP fluorescence intensity with 
increasing concentrations of iron cylinder. 100 µM cylinder caused a reduction by 56 % 
of the control. Despite no statistical significance (p > 0.05, One-way ANOVA), the 
biological trend seen is consistent with that shown in Figure 5.2. Further repeats are 
needed to achieve statistical significance. This data supports that obtained for purified 
protein indicating that the cylinder has the ability to cross the cell membrane and gain 
access to GFP inside living cancer cells and inhibit its action. The higher the 
concentration of cylinder used, the greater the strength of fluorescence quenching 
observed.     
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The precise mechanism by which the drug is able to quench GFP fluorescence in cancer 
cells remains unknown. However, it is tempting to speculate that the cylinder is directly 
interacting with the chromophore to have its effect. The well-known denaturant, 
guanidine disrupts the hydrogen bonding in protein molecules resulting in incorrect 
protein folding. As GFP fluorescence decreases by denaturing, guanidine is considered to 
be a quencher of GFP fluorescence having its effects by bringing about structural changes 
in the protein. The iron cylinder may be acting in the same way with regards to GFP.
7
 
 
5.2.3 Investigating Hoechst Quenching by Iron Cylinder in GFP-Expressing 
MDAMB-231 Cells 
To ensure that the GFP-expressing cell line was similar in every way to the non-
expressing line other than in its expression of the GFP protein, the Hoechst quenching 
experiments (previously done using the MDAMB-231 cell line in Chapter 3) were carried 
out using the GFP-expressing version of these cells. The fluorescence for GFP-expressing 
MDAMB-231 and non-expressing cells was measured at each cylinder concentration 
tested (0, 10, 25, 35, 50 and 100 µM). Cells were treated with Hoechst and then cylinder 
(20 minutes at 37 
0
C for each incubation period). A fluorimeter was used to record the 
fluorescence of each sample (λexc = 340 nm, λem = 460 nm) and three repeats were 
collected for each concentration of iron cylinder used (Figure 5.4). 
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Results obtained for both cell lines revealed a decrease in Hoechst fluorescence caused 
by increasing concentrations of cylinder. Treatment of GFP-expresing MDAMB-231 
with 100 µM cylinder reduced fluorescence intensity by 44 % of then control and 55 % in 
the non-expressing MDAMB-231 cells. This result was found to be statistically 
significant in terms of difference from the control (p < 0.001, One-way ANOVA 
followed by Tukey test) (Figure 5.4). 
 
 
Figure 5.4. Evaluation of Hoechst fluorescence in GFP-expressing MDAMB-231 and 
non-expressing MDAMB-231 cells. Cells were treated for 20 minutes with Hoechst 
followed by 20 minutes with cylinder at 37 
0
C prior to measuring fluorescence via 
fluorimetry. Values are the mean of three separate experiments ± S.E.M. Significant 
difference from control, with p<0.05: *, <0.01: **, <0.001: ***. (One-way ANOVA 
followed by Tukey test).  
 
 
*** 
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The results confirm that the cylinder is able to access the nuclear DNA in both cell lines 
and cause displacement or quenching of the Hoechst dye in both cases. When 
investigating Hoechst quenching, the general trend is similar across both cell types and 
no statistical difference was found between the two cell types (p > 0.05, Two-way 
ANOVA). These results provided further confidence with regards to results obtained for 
GFP quenching in this cell line. Furthermore, despite the slight variation in extent of 
quenching, the trend seen here is similar to that seen in Figure 3.9 with increasing 
concentrations of cylinder causing greater Hoechst quenching.   
 
The intensity of Hoechst and GFP quenching over time was then compared using GFP-
expressing MDAMB-231 cells treated with 50 µM cylinder. This concentration of 
cylinder was chosen as it was previously shown to quench both Hoechst and GFP 
significantly in these cells (Figures 5.3 and 5.4). Two experiments were carried out. In 
the first, cells were treated with Hoechst and then cylinder (20 minutes at 37 
0
C). The 
cylinder containing media was washed away and the fluorescence recorded at 20 minute 
intervals over 3 hours (λexc = 340 nm, λem = 460 nm for Hoechst, λexc = 485 nm, λem = 530 
nm for GFP) (Figure 5.5A). In the second, cells were treated with Hoechst (20 minutes at 
37 
0
C) and then cylinder for 3 hours at 37 
0
C but remained in contact with the cylinder 
over the 3 hour period as the cylinder containing media was not washed away (Figure 
5.5B). The fluorescence was recorded at 20 minute intervals over the 3 hour period (λexc 
= 340 nm, λem = 460 nm for Hoechst, λexc = 485 nm, λem = 530 nm for GFP). The 
fluorescence values shown for each time point were calculated using the average 
fluorescence of three readings.  
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The results show that GFP fluorescence decreases in a time-dependent manner when 
cylinder treatment is washed away. After 3 hours, the GFP fluorescence was reduced by 
58 % of the control which was also left over time like this. Comparatively, under these 
conditions, the fluorescence of Hoechst does not decrease gradually over time. It is 
reduced by 56 % after 20 minutes and does not decrease further over the 3 hours (Figure 
5.5A). When the cylinder remains in contact with cells, GFP fluorescence significantly 
decreases by 62 % and Hoechst by 60 % of the control after 20 minutes of exposure. 
Neither Hoechst nor GFP fluorescence decrease further over the time course (Figure 
5.5B). 
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A 
 
B 
 
Figure 5.5. Evaluation of Hoechst and GFP fluorescence in GFP-expressing MDAMB-
231 cells exposed to 50 µM cylinder over time. Cells were treated for 20 minutes with 
Hoechst followed by treatment with cylinder at 37 
0
C. A: Cylinder containing media was 
washed away prior to measuring fluorescence via fluorimetry. B: Cylinder containing 
media remained in contact with cells and fluorescence measured via fluorimetry. Values 
are the mean of three separate experiments ± S.E.M. Significant difference from control, 
with p<0.05: *, <0.01: **, <0.001: ***. (One-way ANOVA followed by Tukey test).  
** 
*** 
*** 
*** 
*** 
*** *** *** 
*** *** 
*** *** 
*** *** 
*** *** *** *** 
*** 
*** *** *** *** *** *** *** 
*** 
*** 
*** *** 
*** *** *** *** 
*** *** 
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These results indicate that treatment of GFP-expressing MDAMB-231 cells with 50 µM 
cylinder for 20 minutes is sufficient for quenching both the Hoechst and GFP signals. As 
the GFP and Hoechst did not decrease further after 20 minutes of exposure to cylinder 
this suggests that within 20 minutes the cylinder is able to cross the cell membrane and 
have its effect. It is able to cross the nuclear membrane and bind to the DNA causing a 
displacement or quenching of Hoechst in addition to crossing the cell membrane and 
gaining access to the GFP chromophore causing inhibition possibly via structural changes 
in the protein. The results show that both Hoechst and GFP signals are quenched to 
similar extents (significantly reduced by around 60 % of the controls) when treated for 20 
minutes with 50 µM cylinder. This data supports our previous findings where a range of 
concentrations of cylinder were tested over 20 minutes (Figures 5.3 and 5.4).  
 
These results have allowed us to show that the concentration of cylinder used is far more 
important than the incubation period over which cells are exposed to it. 20 minutes 
appears to be a sufficient time point for the cylinder to have its effects. In these results, 
complete inhibition of GFP and Hoechst does not occur. This may be due to binding of 
Hoechst non-specifically to cellular targets with which the cylinder is not able to 
compete. Hoechst may be bound to RNA and so the signal is still present but not 
quenched by the cylinder. An excess of GFP may be responsible for the lack of complete 
inhibition of signal.    
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Results from Chapter 3 for MDAMB-231 cells treated with 50 µM iron cylinder for 20 
minutes showed that Hoechst fluorescence was reduced by 79 % of the control. Results 
obtained here for the GFP-expressing MDAMB-231 cell line show a similar effect with 
Hoechst fluorescence reduced by 64 % under the same experimental conditions providing 
further support for previous findings. The cylinder may preferentially quench 
fluorescence from GFP than from Hoechst which could explain the greater reduction in 
Hoechst fluorescence seen in the non-expressing cell line.  
 
5.2.4 Investigating Quenching of Nuclear GFP 
Since the cylinder binds to DNA which is contained in the nucleus, it is of interest to 
investigate whether the GFP signal it appeared to quench was specifically nuclear. To test 
this confocal microscopy was used to image the nuclei of GFP-expressing MDAMB-231 
cells. GFP-expressing MDAMB-231 cells were grown in MatTek dishes and treated with 
50 µM iron cylinder for 20 minutes. Images were acquired at the beginning and the end 
of the cylinder treatment period. The fluorescence of the nucleus was monitored visually 
for changes (Figure 5.6).  
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 A Time: 0 minutes        Time: 20 minutes 
 
 
 
 
 
 B Time: 0 minutes        Time: 20 minutes 
 
 
 
 
Figure 5.6. Confocal imaging showing fluorescent and brightfield images of GFP-
expressing MDAMB-231 cells treated for 20 minutes with 50 µM iron cylinder. A: 
Fluorescent and brightfield images of untreated control cells imaged at the start and end 
of the 20 minute period. B: Fluorescent and brightfield images of cells imaged 
immediately after cylinder treatment and 20 minutes after cylinder treatment. 
 
Results show a clear visual decrease in the nuclear fluorescence of cells treated with 
cylinder at the end of the treatment period. Comparatively, control cells which were 
untreated do not show any visible reduction in the fluorescence signal over the time 
period imaged. Bright field images reveal that the cells were intact and therefore any 
decrease in fluorescence can be attributed to the treatment undergone. We hypothesize 
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that the cylinder enters the cell, crosses the nuclear membrane and interacts with the GFP 
chromophore resulting in quenching of fluorescence. 
 
5.3 Conclusions and Future Work 
The results have provided evidence for the cylinder’s ability to quench the green 
fluorescent protein, possibly from the nucleus. In order to confirm this, the cylinder’s 
ability to quench fluorescence from the cell cytoplasm and organelles would need to be 
further investigated and quantified. Cellular components transfected with GFP followed 
by treatment with cylinder and isolation would provide further insight into the cylinder’s 
preferential route of quenching GFP. The rate at which nuclear Hoechst is quenched by 
cylinder can be compared with the rate of GFP by using GFP-tagged nuclear proteins and 
monitoring the fluorescence over a time course at a range of cylinder concentrations. In 
addition, red fluorescent protein (RFP) could also be tagged and targeted to different 
organelles.   
 
These results have important potential applications in vitro and in vivo for the cylinder 
because GFP can be stably expressed in a range of tumour cells which can be implanted 
into animals. Since the cylinder quenches GFP this could serve as a tool to image 
cylinder uptake and localization in vivo. It could help to further investigate the 
mechanism and route by which the cylinder enters cells and has its effects. GFP animal 
models are readily available, have stable expression and don’t require additional factors 
to fluoresce making this protein ideal to use for tracking the progression of tumours.
1
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CHAPTER 6 
 
 
 Investigating In Vitro and In Vivo Toxicity of Iron Cylinder  
 
Zebrafish research was carried out at the Institute of Biomedical Research in the Medical 
School at the University of Birmingham. Egg collection and micro-injection was carried 
out by Dr. Y. Hadzhiev. 
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6.1 Introduction 
In addition to assessing toxicity and investigating the effects of a potential anticancer 
agent in vivo, it is important to investigate toxicity in vitro using specific cancer cells of  
interest. This allows researchers to study the direct effects of the drug on mammalian 
cells and do so in the absence of intervening factors. Genotoxic agents induce DNA 
damage which can lead to mutations that can later form tumours and a number of in vitro 
methods exist to test the genetic toxicity of a drug.
1
 The Comet assay is a single cell gel 
electrophoresis assay which provides a fast and sensitive measure of single and double 
stranded breaks in the DNA of cells. Two variants of the assay exist namely alkaline and 
neutral comet assay. It has been suggested that the variants distinguish between types of 
damage with the neutral assay preserving the double-stranded DNA structure and 
therefore only detecting double stranded breaks. Comparatively the alkaline comet assay 
is believed to be much more sensitive and able to detect both single and double strand 
DNA breaks.
1
   
 
This assay has been used to assess the genotoxic potential of drugs such as cisplatin 
which despite being an effective anticancer drug, is highly cytotoxic.
2
 As cisplatin is not 
specific in its action, genetic damage can result in unaffected tissues leading to 
accumulation of mutations and secondary tumors several years after cessation of 
treatment.
2
 In addition to its genotoxicity, many tumours have also acquired resistance to 
this drug (see section 1.5). These drawbacks have prompted research into developing new 
anticancer drugs which can have their effects in the absence of genotoxicity. 
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An essential part of determining safe and effective dosage for novel drugs to be used in 
the clinic is a good understanding of the drug’s performance using in vivo systems. 
Despite the fact that significant advances have been made using established cell lines, to 
progress further animal models are required which more closely resemble the 
heterogeneous nature of human tissues.
3
 In comparison to cell-based systems, research 
using in vivo systems is particularly important as they provide good physiological models 
that more closely resemble the complex environment within the human body. Results 
from these studies can be used to help in the design of clinical trials and establish the 
likely effects a drug will have when administered to a patient.
4 
The zebrafish is a popular 
vertebrate model organism used in medical research due to its small size and ease of 
culture. They offer a range of advantages including the clear visualization of complex 
developmental processes from embryo to adulthood with the process of embryogenesis in 
humans closely resembling that displayed during zebrafish development. Furthermore, 
the embryos are clear and develop rapidly outside the parent making it possible for 
researchers to visualize the embryo across developmental stages including the 
materialization of internal organs.
5
  
 
In addition to these advantages, the numbers of offspring produced allows high 
throughput screening to be conducted relatively cheaply which would not be possible 
using other model organisms such as rodents. Numerous mutations have been identified 
in zebrafish which cause disruptions in the developing embryo. These mutants have 
provided accurate models for a number of human diseases including immunological 
disorders and cancers. Research using these models can provide information about genes 
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responsible for various processes in human development.
5
 Furthermore, experiments on 
zebrafish embryos and early larvae (less than 6 days after hatching) do not require a 
Home Office license in the UK as The Animals Scientific Procedures Act (1986) only  
regulates  fish  from the time at which they become capable of independent feeding.
6
  
 
In this chapter the previous in vitro work is moved forward to a whole organism using the 
in vivo zebrafish model. The toxicity of iron cylinder in this organism is investigated and 
compared with that of cisplatin. Phenotypic changes occurring in the developing embryo 
in response to treatment are examined and the genotoxic potential of iron cylinder is 
investigated in relation to cisplatin using the comet assay.  
 
6.2 Results and Discussion 
6.2.1 In Vivo Imaging 
 
 
 
Figure 6.1. Representative image of a zebrafish embryo 5 hours post fertilisation (hpf) 
obtained by bright field microscopy. 
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Due to its large number of virtues, the zebrafish was chosen as a model to further 
investigate the iron cylinder. In chapter 3, a novel method was developed to indirectly 
image the non-fluorescent iron cylinder via its quenching of nuclear Hoechst 
fluorescence. Here, the use of zebrafish takes this work further to allow Hoechst 
quenching to be monitored in vivo. This provides a working animal model allowing direct 
imaging of the cylinder having its affect in an organism. This could also allow 
distribution of the drug to be visualized through its quenching mechanism. Initially, 
embryos were incubated in a range of Hoechst concentrations. However, poor penetration 
of the dye prevented any staining of nuclei with a range of concentrations tested.  
 
Mature eggs of zebrafish embryos are surrounded by a protective membrane known as 
the chorion. The process of dechorionation carefully removes this membrane (manually 
using a sharp steel needle) allowing better microscopic observations as well as improving 
the access of an external compound to the embryonic cells. Dechorionated embryos were 
incubated into Hoechst solutions with the aim of improving dye penetration in the 
developing embryo. However, confocal microscopy revealed similar results to embryos 
with their chorion intact, with no penetration of dye. Higher concentrations of dye and 
longer incubation periods were explored (up to 100 µM for 5 hours) but the results 
obtained did not reveal sufficient staining. Concentrations of over 50 µM resulted in 
embryo death after 5 hours.  
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An alternative strategy was then used which involved directly micro-injecting Hoechst 
into the embryos. Dechorionated zebrafish embryos at one-cell stage were injected by 
hand with 25 µM Hoechst (final concentration) and incubated at 28 
0
C. Images were 
acquired 5 hpf using confocal microscopy (Figure 6.2) 
 
 
 
Figure 6.2. Confocal imaging showing fluorescent and brightfield images of zebrafish 
embryos (5 hpf) injected with 25 µM Hoechst at one-cell stage.  
 
Confocal imaging results revealed a very speckled non-specific Hoechst signal which 
was distributed throughout the cells and the yolk. When untreated control embryos were 
imaged, a similar image was produced. Due to the high background UV fluorescence in 
the zebrafish embryos and possible trapping of the dye in the hydrophobic yolk, 
quenching in vivo upon administration of iron cylinder could not be monitored.         
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6.2.2 In Vivo Toxicity Studies 
The toxicity of the cylinder in zebrafish was investigated and compared with the 
toxicities of Hoechst and cisplatin. This is an important part of drug development to 
establish therapeutic concentrations of novel drugs in a whole organism. Survival of 
zebrafish embryos was monitored after treatment with Hoechst, iron cylinder or cisplatin 
to determine a non-toxic concentration range for treatment. Embryos at one-cell stage 
were injected by hand with 10 or 100 µM compound and incubated at 28 
0
C. Survival 
was quantified by counting live embryos at 4 and 24 hpf. The percentages of viable 
embryos shown in the results were calculated using the average count of three 
experiments (Figure 6.3).  
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A 
 
B 
 
Figure 6.3. Evaluation of toxic effects of Hoechst, Iron cylinder and Cisplatin treatment 
in zebrafish. Embryos were injected with compound and survival monitored by counting 
viable embryos over 4 hours (A) and 24 hours (B). Controls were injected with phenol 
red. Values are the mean of three separate experiments ± S.E.M. Significant difference 
from control, with p<0.05: *, <0.01: **, <0.001: ***. (One-way ANOVA followed by 
Tukey test). 
* 
** 
*** 
*** 
*** 
*** 
*** 
** 
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The results show that treatment of embryos with 10 µM Hoechst, cylinder or cisplatin for 
4 hours did not cause any significant decrease in survival of embryos with over 87 % 
remaining viable for each compound tested. Comparatively, treatment with 100 µM 
Hoechst, cylinder or cisplatin for 24 hours decreased survival to less than 25 % of the 
control with very high statistical significance (p < 0.001). The embryos appear to be more 
resistant to the effects of the cylinder as opposed to cisplatin at this time point (24 % 
survived cylinder treatment as opposed to 16 % for cisplatin treatment). These results 
indicate that concentrations of 100 µM cylinder are directly toxic to zebrafish and 
therefore should not be used for testing the effects of this drug in vivo (Figure 6.3).  
 
Treatment of embryos with 10 µM cylinder for 24 hours reduced survival to 83 %. 
Comparatively, for embryos treated with 10 µM cisplatin, survival was reduced to 66 % 
after 24 hours. This provides a large therapeutic window for the iron cylinder over which 
it can be administered to have its beneficial effects without causing death to the organism 
(Figure 6.3). Results show that 100 µM Hoechst treatment reduced survival to 19 % after 
24 hours. Hoechst toxicity data supports the earlier results where Hoechst was injected 
into embryos for imaging purposes with death resulting from treatment with 100 µM.  
 
Figure 6.4 shows representative images acquired for the embryos monitored for survival. 
Treatment of embryos with compound resulted in a developmental delay when compared 
to untreated control embryos. The higher concentration (100 µM) caused abnormal cell 
growth with cells moving away from the yolk as opposed to spreading around it. 
Eventually, the cells detached from the yolk and the embryo disintegrated.  
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A          4 hours     24 hours 
                          
B          4 hours     24 hours 
                          
C          4 hours     24 hours 
                           
D          4 hours     24 hours 
                           
Figure 6.4. Brightfield images showing zebrafish embryos injected at one-cell stage with 
100 µM compound. (A) Brightfield images of untreated control embryos imaged at 4 hpf 
and 24 hpf, (B) Brightfield images of Hoechst treated embryos imaged at 4 hpf and 24 
hpf, (C) Brightfield images of iron cylinder treated embryos imaged at 4 hpf and 24 hpf, 
(D) Brightfield images of Cisplatin treated embryos imaged at 4 hpf and 24 hpf.  
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6.2.3 In Vitro Genotoxicity Studies 
Genotoxicity is one of the major drawbacks of anticancer agents currently in use such as 
cisplatin. The comet assay is a single cell gel electrophoresis assay which allows sensitive 
detection of single and double strand breaks in the DNA. In this assay, the larger the 
comet tail, the greater the number of DNA strand breaks present. Neutral and alkaline 
conditions are two variations of the comet assay method. The prevailing view is that the 
neutral version detects double stranded breaks and the alkaline version detects both single 
and double stranded breaks in DNA.
5
 However, this is the subject of some debate with 
some authors proposing that using a pH close to neutral does not specifically identify 
double-stranded breaks.
8
 
  
 
Alkaline and neutral comet assays were carried out to detect DNA strand breaks in the 
HL60, human myeloid leukemia cancer cell line. Cells were treated with 25 µM 
compound for 8 hours prior to cell lysis, staining of the DNA and electrophoresis. The 
mean % tail intensity obtained from comets was calculated using the average of three 
readings (Figure 6.5).   
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Figure 6.5. Evaluation of genotoxic effects of treatment in HL60 cells using the comet 
assay. Cells were incubated with 25 µM compound for 8 hours prior to obtaining mean 
% tail intensity.  Values are the mean of three separate experiments ± S.E.M. Significant 
difference from control, with p<0.05: *, <0.01: **, <0.001: ***. (One-way ANOVA 
followed by Tukey test).  
 
Results show that treatment with 25 µM cylinder for 8 hours did not cause any significant 
increase in mean % tail intensity (1 % of the control for both neutral and alkaline comet 
assays). This indicates that treatment with cylinder does not cause production of single or 
double strand breaks in DNA at this concentration and time point. This is positive for the 
potential of iron cylinder as a cancer drug as it can have its effect in cancer cells and do 
so in the absence of genotoxicity. Treatment of tumours with potent genotoxic drugs may 
result in secondary tumours occurring in patients years after treatment has ceased. 
Comparatively, cisplatin treatment at the same concentration and timepoint resulted in an 
increase to 48 % mean tail intensity under alkaline and 25 % under neutral conditions of 
** 
*** 
*** 
** 
*** 
*** 
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high statistical significance (p < 0.01, One-way ANOVA). These results indicate that 
exposure of leukemic cells to cisplatin causes single and double stranded breaks in DNA 
as expected. 
     
Etoposide binds to DNA and inhibits the topoisomerase enzyme required for the 
unwinding of DNA. During DNA replication, strand breaks occur and trigger cell suicide 
mechanisms.
7
 Results show that treatment with 25 µM etoposide for 8 hours increased 
mean % tail intensity to 76 % in the alkaline and 82 % in the neutral comet assay with 
very high statistical significance (p < 0.01, One-way ANOVA). These results are as 
expected with etoposide being a potent inducer of double strand breaks as indicated by 
results for the neutral comet assay. Similarly, treatment with cylinder and etoposide 
together resulted in increased % mean tail intensity (81 % and 82 % for alkaline and 
neutral conditions respectively). The results indicate that cylinder in the presence of 
etoposide does not have any protective role to reduce the DNA damage resulting from 
etoposide treatment. Moreover, it indicates that the cylinder’s ability to coil and compact 
DNA is not masking the presence of strand breaks, since the etoposide tail intensity is not 
reduced in the presence of cylinder. This is good evidence that the cylinder is indeed not 
a strand break agent and that its coiling ability is not creating a false negative result in the 
comet assay.   
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6.3 Conclusions and Future Work 
The results have further provided evidence for the non-genotoxic nature of iron cylinder. 
In comparison to the cancer chemotherapeutics, etoposide and cisplatin, the cylinder does 
not induce significant production of single or double strand breaks in the DNA of 
leukemia cells as assessed by neural and alkaline versions of the comet assay.  
 
Treating zebrafish embryos with 100 µM cylinder for 24 hours had a similar effect to that 
seen with in vitro cell testing. HL-60 leukemia cells treated with the same concentration 
and timepoint resulted in direct cytotoxicity and only necrotic cells being identified.
9 
Embryos injected with 10 µM cylinder for 24 hours showed a significant decrease in 
survival when compared to the control. Using in vitro cell systems, an increase in 
apoptotic cell numbers was observed in HL-60 cells treated for 24 hours with 10µM 
cylinder .
9 
The in vivo results obtained here support data published previously for tumor 
cell lines. This implies that injecting 10 µM cylinder for 24 hours in zebrafish embryos 
induces apoptotic cell death and increasing this concentration to 100 µM causes necrotic 
cell death as seen by the significant decrease in embryo survival rate.       
 
This is the first in vivo research conducted for the iron cylinder using the model system of 
zebrafish embryos. The direct micro-injection results have indicated that the 
concentration of cylinder tolerated in this organism is between 10 and 100 µM. This 
provides a large therapeutic window over which the cylinder can bring about its effect. 
Morphological changes in the developing embryo have been observed upon cylinder 
treatment which may provide further insight into its localization and distribution in vivo. 
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CHAPTER 7 
 
 
 Conclusions and Future Work  
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In this thesis, the iron cylinder has been investigated as a quencher of nuclear Hoechst 
fluorescence in a range of cancer cell lines. Flow cytometry and fluorimetry have 
quantified quenching occurring in a concentration-dependent manner at the population 
level in a range of cancer cell types. These results provide evidence for the cylinder being 
able to cross the cell/ nuclear membrane and interact in close proximity of the Hoecst 
bound in the DNA minor groove. As the cylinder was designed to be the right size and 
shape to fit perfectly into the major groove spanning five base pairs, data obtained here 
suggests the quenching observed is due to strong binding of the iron cylinder at this 
location.
1
 Previous studies looking at the crystal structure of the cylinder found no 
significant disturbances in the DNA when cylinder was bound which further supports the 
cylinder’s perfect fit in the major groove.2  
 
This work has shown that the cylinder can get into a range of tumour types within 20 
minutes and is effective at concentrations as low as 10 µM. This data supports previous 
findings where Hoechst-loaded HL60 cells were treated with cylinder and the 
fluorescence spectra produced identified the displacement.
3
 The work in this thesis has 
further expanded the current knowledge base by finding that the cylinder can penetrate 
the cell membrane of adherent and suspension tumour cells when administered in growth 
media for short periods of time. Furthermore, epifluorescence microscopy has allowed 
visual observations of the quenching in these cells. Ovarian cancer cells have shown a 
greater resistance to the cylinder’s effects when compared with breast cancer and 
leukaemia cell lines. This finding is of interest as many ovarian cancers have developed 
resistance to the classic chemotherapeutic, cisplatin.
4,5
 Therefore, giving the cylinder an 
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advantage as SKOV3 cells showed sensitivity to this compound albeit reduced when 
compared to the other cancer types investigated. A novel idea has been developed in this 
thesis which provides exciting possibilities allowing indirect fluorescent imaging of non-
fluorescent compounds through the exploitation of their binding nearby a bound 
fluorescent stain.        
 
Experiments were conducted to optimize the concentrations of substrates required (1 mM 
luciferin and 1 mM ATP) to produce luminescent signals from luciferase-expressing 
breast cancer cells. Once achieved, experiments were conducted using lysed cells and 
trypsinized cells to investigate iron cylinder’s effects on light emission in the absence of 
cell adhesion factors. Following on from the success achieved in this work, adherent 
luciferase-expressing cells were used finally to confirm the results. The discovery made 
during this research about iron cylinder’s inhibition of luciferase is unprecedented and 
provides new possibilities by which the location of cylinder can be tracked. 
 
The cylinder has been shown to directly affect light emission in a concentration-
dependent manner and a concentration of 10 µM cylinder has been found to be sufficient 
at inhibiting the emission from luciferase-modified breast cancer cells. The cylinder may 
be physically interacting with the ATP-luciferase complex and preventing the enzyme 
from accessing the substrate required for the bioluminescent reaction to proceed. Further 
insight was provided by investigating changes in the intensity of inhibition over time. 
Data obtained identified the flash kinetic nature of the enzymatic reaction as the signal 
produced decreased rapidly. This highlighted the importance of obtaining measurements 
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rapidly upon substrate addition and the need to maintain consistency across experiments 
to produce reliable data. The work carried out provides further opportunities for imaging 
by monitoring the inhibition of luminescent enzymes. 
 
Starting with the use of purified green fluorescent protein (GFP), the idea that cylinder 
could quench GFP fluorescence in cells was explored further in GFP-modified breast 
cancer cells using fluorimetry and confocal microscopy. Results from this work identified 
that treatment of GFP-modified breast cancer cells with 50 µM cylinder for 20 minutes 
resulted in dramatic GFP quenching and the signal was not further quenched when cells 
were in contact with the cylinder for a longer period. These findings complement those 
obtained for Hoechst quenching experiments and expand on the current knowledge of the 
cylinder confirming that it is able to enter the nucleus and bind to the DNA within 20 
minutes.  
 
In addition to decreasing Hoechst fluorescence, iron cylinder’s ability to competitively 
displace ethidium and propidium from DNA has previous been shown.
3
 However, the 
discovery that iron cylinder quenches GFP fluorescence and can do so from intact cells 
has not previously been reported in the literature. These results are of great potential 
importance as the expression of the protein in tumours of could serve as a tool to image 
uptake and localization both in vitro and in vivo. 
 
During the course of the experiments carried out in this thesis, the iron cylinder’s 
genotoxicity was investigated in relation to the DNA crosslinker, cisplatin and the 
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topoisomerase inhibitor, etoposide. This work has supported current literature confirming 
that both of these widely used chemotherapeutics cause DNA single and double stranded 
breaks.
6,7
 In contrast, the iron cylinder was found not to be genotoxic in leukemic cells. 
Previously, the comet assay has been carried out in ovarian and leukemic cell lines 
treated with cylinder for 24 hours.
3
 This published data revealed no evidence of cylinder-
related genotoxicity which strengthens the findings from this current research and favours 
its potential as an effective anticancer agent.  
 
The work in this thesis expands the current knowledge of the cylinder’s genotoxic 
potential as two versions of this assay have been investigated. The neutral version detects 
only double stranded breaks and the alkaline version is able to detect both single and 
double stranded structures. This research has confirmed that the cylinder is not genotoxic 
through either version of the comet assay. Furthermore, the novel combination of 
etoposide plus cylinder was tested and results showed that the presence of cylinder 
offered no form of protection with no reduction in damage to DNA caused by etoposide 
in cells. This work expanded on previously reported atomic force microscopy data 
showing the cylinder’s ability to induce intramolecular DNA coiling.8 Here it was 
confirmed that the cylinder does not cause strand breaks and its coiling is not creating a 
false negative result in the comet assay by masking the presence of strand breaks. The 
genotoxicity research could be extended to further investigate the cylinder when treated 
on cells with significant DNA strand breaks induced by other treatments.          
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Prior to the work carried out in this thesis, iron cylinder’s effects in a whole organism had 
never been studied. In chapter six, the toxicity of iron cylinder was investigated in the 
model organism, zebrafish for the first time. A concentration of 10µM cylinder injected 
directly into embryos has been found to not kill the organism. In previously published 
literature, this concentration induces some (but not total population) apoptotic cell death 
in cancer cells in vitro.
3
 This might explain the increased survival seen in vivo at 10µM 
when compared to 100 µM. In cancer cells, 100µM cylinder has been found to cause cell 
death by necrosis which may also be the mechanism causing death in vivo for this 
concentration.
3
 Drugs with small therapeutic windows require close monitoring of plasma 
levels to maintain effective dosages in patients.
9
 Therefore, the novel finding which 
indicates a large therapeutic window over which the cylinder can elicit its therapeutic 
response in the absence of toxicity is advantageous for its potential as a safe drug.  
 
In the literature, iron cylinder has been shown to be up to five times less toxic than 
cisplatin in a variety of cancer cells with mitochondrial toxicity values comparable to the 
drug carboplatin which has fewer side effects.
3 
Initial findings from the work carried out 
in zebrafish embryos indicate that the cylinder is less toxic than Hoechst and cisplatin 
over 24 hours which is in support of published in vitro data. Furthermore, it would be 
expected that the cylinder is less toxic than cisplatin in vivo as has already been identified 
in vitro through the use of the comet assay. However, to strengthen the zebrafish data and 
make the results more conclusive, further studies need to be carried out examining a 
greater range of concentrations and time points. A developmental delay and phenotypic 
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changes occurring in embryos in response to cylinder treatment have also been observed 
which can provide further information about its mechanism of action in vivo.  
 
There is a need to carry out epifluorescence microscopy as described in chapter three but 
with cylinder concentrations ranging from 0 to 100 µM. Quantification of the fluorescent 
images produced by measuring changes in pixel intensity of nuclear Hoechst would 
provide further support for the data acquired. The differences observed in the uptake of 
cylinder between cancer cell types can be further investigated by using inhibitors of 
specific transporters prior to treatment. The use of in vivo knockout mouse models, 
deficient in certain drug transporters can provide further insight into the mechanism by 
which cylinder is absorbed across cell membranes. Further work to precisely confirm the 
location of iron cylinder in the nucleus should also be conducted using the synchrotron 
light source to carry out elemental mapping using X-ray absorption spectroscopy.  
 
From chapter four the need arises to investigate the iron cylinder’s quenching of the 
luminescence signal in a whole organism. Cancer cells stably expressing luciferase can 
be transplanted subcutaneously into a small animal such as a mouse. After supplying the 
substrates required for the bioluminescence reaction to occur, iron cylinder would be 
injected into the animal possibly through the tail vein. The absorption and distribution of 
the cylinder would then be tracked in the cancer cells by its inhibition of the emitted 
light. This system would serve as an indirect imaging tool to further investigate 
interactions of the cylinder in an in vivo system.  
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The data obtained from experiments carried out in chapter four was through the use of 
luciferase-modified breast cancer cells. Therefore, to take this research further it is 
important to explore ovarian cancer cells with respect to inhibition of light emission by 
iron cylinder. A greater resistance to the effects of cylinder when compared to breast 
cancer cells would be predicted and this data could further support results obtained in 
chapter three where increased sensitivity of breast cancer cells to fluorescence quenching 
by iron cylinder has been observed. 
 
As GFP animal models are readily available, have stable expression and don’t require 
additional factors to fluoresce, this makes this protein ideal to use for tracking the 
progression of tumours. The gene that encodes GFP can be inserted into zebrafish 
embryos to allow integration into the animal’s genome. Treatment with cylinder would 
then occur and the cylinder could be monitored by its fluorescence quenching. This 
would allow changes in the distribution and accumulation of cylinder in the developing 
zebrafish to be studied. The same principle could be applied to GFP-mouse models.  
 
Quenching of purified green fluorescent protein by iron cylinder should be carried out 
using concentrations below 10 µM as this has not been investigated. Furthermore, as 
GFP-quenching has only been studied in breast cancer cells during the research carried 
out in this thesis, it is important to make sure other cancer types are also investigated. It 
would be especially interesting to see how the extent of the quenching compares across 
ovarian and leukemic cell lines.  
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A cancer cell line expressing a nuclear GFP fusion protein could be used to investigate 
cylinder quenching GFP from the nucleus. A range of cylinder concentrations (0-100 
µM) could be tested and the fluorescent images obtained through microscopy could be 
quantified. Analysis of nuclear GFP quenching occurring at the population level could be 
quantified through the use of fluorimetry and flow cytometry. The results obtained could 
then be compared with the same cancer cell line expressing cytoplasmic GFP. Further 
insight would be gained about whether the cylinder preferentially quenches nuclear or 
cytoplasmic GFP by testing this over a time course.    
 
Work arising from chapter six has revealed the need for Hoechst quenching by iron 
cylinder to be repeated using an alternative in vivo model. Due to high background in the 
UV, zebrafish have been identified as unsuitable organisms for monitoring the quenching 
of this dye. An alternative dye in the red or green region of the spectrum would be better 
suited for use in zebrafish embryos. However the dye would first need to be identified 
and all the in vitro research carried out prior to experiments in the animal. Zebrafish can 
provide an interesting model to further investigate phenotypic changes occurring as a 
result of cylinder treatment at different embryonic stages. This can provide further details 
about the localization of the cylinder in specific tissues and organs. 
 
It would be very interesting to study iron cylinder toxicity and its anticancer properties 
using mice as model organisms. The results would further support toxicity data obtained 
from the zebrafish research carried out in this thesis. A clear understanding of cylinder 
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concentrations that can be tolerated in vivo as well a sound understanding of its 
mechanism of action are essential to its potential for progression to the clinical trial stage.  
 
In conclusion, progression to whole-body imaging using small animals is the next step to 
further the work across all chapters. In this thesis, biological and imaging studies have 
been carried out on the supramolecular helicate (iron cylinder) and indirect methods to 
image this non-fluorescent compound have been developed. The cylinder’s effects on the 
nuclear stain, Hoechst, the enzyme luciferase and the green fluorescent protein have 
allowed this to be achieved. The iron cylinder’s activities on luciferase and GFP can be 
used as a way to visualize its location as well as monitoring and visualizing the tumour in 
vivo. This work has concluded that bioluminescent and fluorescent imaging can provide 
sensitive and quantifiable data for the rapid evaluation of cylinder efficacy.   
 
This thesis has also pioneered the first in vivo research relating to the iron cylinder. Using 
zebrafish embryos as model organisms, the toxicity of the cylinder in relation to the 
classic anticancer drug, cisplatin has been investigated and results show promising novel 
evidence for its use in clinic in the near future. Development of a fluorescent version of 
the iron cylinder would provide a much enhanced imaging tool. However, its synthesis 
may pose challenges which highlight the need to develop methods to indirectly image the 
cylinder such as those developed in this thesis.  
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